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Abstract 
 
The use of nano/meso-particles (NP/MP) as constituent of topical formulations of drug and 
cosmetics has been a topic of considerable interest for the past 20 years. However, the transport 
mechanism of nanoparticle-associated drug/active following topical application on the skin is still 
unclear. No general answers have been obtained to such questions as the depth of intact NP 
penetration into the skin, the skin distribution of active substances, and the fate of the vehicles 
on/in the skin.  
 
The main objective of this thesis, therefore, was to observe the in vitro penetration of 
fluorescently-labeled nanoparticle vehicle and “active” on/within the skin by using laser 
scanning confocal microscopy (LSCM). Furthermore, the concentration profile of the “active” 
in the outermost skin layer, stratum corneum, has been assessed by using tape stripping 
technique combined with HPLC analysis. The factors, including particle size, hydrophobicity, 
shell thickness of nanocapsules and surface charge, have been investigated with regard to their 
abilities to influence the penetration of “active” into the skin. The methods for NP preparation 
and characterization have also been developed.  
 
The results demonstrated that the delivery of “active” into the stratum corneum from NP/MP 
were influenced by a number a factors, including particle size, hydrophobicity, surface charge 
and shell thickness of capsules. The “active” delivery (i) is greater from larger vectors; (ii) 
increases as the hydrophobicity of NP/MP increases; (iii) is favoured by cationic NP; (iv) is 
favoured from capsules with a smaller shell thickness. NP vehicle and “active” mainly 
co-localize in skin “furrows” and around hair follicles after topical application. No evidence 
shows NP penetrate beyond the superficial layer of the skin. In the stratum corneum, the 
“active” remains in part associated with NP, but the release f the “active” clearly occurs to some 
extent followed by its penetration into deep layers of the stratum corneum. Overall, through this 
work, the fate of nanoparticle vehicle and the “active” has been distinguished and the 
physicochemical properties of the nanoparticles that determine their behaviour once applied to the 
skin, and the kinetics with which an “active” is released, has also been understood.  
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Applications of nanoparticles in topical drug 
delivery and in cosmetics 
 
Xiao Wu1 and Richard H. Guy1 
 
1Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, BA2 7AY, Bath, UK 
 
 
Abstract 
The delivery of drugs and active agents to the skin by formulations containing nanoparticles 
is a topic of considerable current interest. A number of studies have shown important 
advantages of these nanostructure-based delivery systems over conventional formulations. This 
review describes the composition, preparation, and characteristics of a wide range of novel 
vectors, including nanoemulsions, liposomes, transfersomes, solid lipid nanoparticles, 
polymeric nanoparticles, ethosomes and niosomes.  
 
Keywords: Nanoparticles, skin, stratum corneum, cosmetics, pharmaceutics 
1.1 Introduction 
 
The skin is the largest organ in the human body by weight, contributing about 10% of total 
weight, and covering an average area of 1.7 m2. It regulates water and heat loss, and prevents 
the invasion of noxious chemicals and microorganisms. Because skin is an easily accessible 
organ, its potential as an alternative route for administering drugs for both systemic and local 
effect has attracted considerable interest [1]. Equally, a large segment of the cosmetic industry 
is focused on the delivery of “actives” to and into the skin. However, molecules do not easily 
penetrate the skin because of its excellent barrier function. As a result, various nano-carriers 
have been developed in an attempt to reversibly modulate the skin barrier and/or to provide 
novel delivery systems for the active of interest. These particulate carriers include 
nanoemulsions, liposomes, transfersomes, solid lipid nanoparticles, polymeric nanoparticles, 
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ethosomes and niosomes. A schematic representation of their structures is shown in Figure 1.1. 
 
 
Figure 1.1: Schematic representation of (a) a nanoemulsion, (b) polymeric nanocapsules, (c) 
polymeric nanospheres, (d) individual liposomes, (e) an ethosome, (f) a transfersome, and (g) a 
niosome. 
 
1.2 The structure of the skin 
 
The skin consists of the epidermis and the dermis, which sits on a layer of subcutaneous fat.  
 
The epidermis contains four histologically distinct layers, from the innermost stratum basale 
via the stratum spinosum and stratum granulosum (SG) to the superficial stratum corneum 
(SC). The SC has been represented as a “brick and mortar” structure [2] in which the 
corneocytes are embedded in an intercellular lipid matrix. The corneocytes comprise insoluble 
keratins enveloped by cross-linked proteins, and are arranged in parallel, overlapping, 
multicellular stacks perpendicular to the skin surface [1]. The inter-corneocyte space is filled 
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with lipids, usually present in the crystalline phase [3]. Most SC lipids are synthesized in the 
viable epidermis during differentiation [4], they are released into the intercellular spaces at the 
SG-SC interface from lamellar bodies. The major SC lipids are ceramides, fatty acids and 
cholesterol. Eight classes of ceramides have been identified. The lipids are arranged in multiple 
bilayers with a periodicity of about 13 nm. Unlike almost all other membranes in the body, the 
SC does not contain phospholipid [2]. This “brick and mortar” structure is now accepted as the 
location of the skin’s excellent permeability barrier, and the SC is the rate-limiting barrier to 
the transcutaneous penetration and absorption of most chemicals following topical 
administration [5].   
 
There are three possible pathways of molecular penetration across the SC: (i) intercellular 
via the lipids between the corneocytes; (ii) transcellular crossing through the corneocytes and 
the surrounding lipids; (iii) appendagal via follicles and sweat ducts (Figure 1.2) [6]. The 
principal route is generally believed to be intercellular. Some permeation enhancers (e.g., oleic 
acid) and vesicular carriers are thought to disorder the SC lipids and facilitate transport across 
the skin [7-9].  
 
Figure 1.2: Skin permeation pathways. 
 
Underlying the SC is the viable epidermis, the thickness of which is typically ~100 µm, 
ranging from as little as 50 µm to around 800 µm on the load-bearing palms and soles of the 
feet [1]. The principal cells of the viable epidermis are keratinocytes, but there are also 
melanocytes, Langerhans cells, migrant macrophages and lymphocytes [10]. However, there 
are no blood vessels in the epidermis.  
 
The dermis is typically 3–5 mm thick and is the major component of human skin. It is rich 
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in blood vessels, lymphatic vessels and nerve endings. The skin appendages, which include 
hair follicles, sebaceous glands and sweat glands, also originate in the dermis. This layer 
resembles an aqueous gel and is a minimal barrier to drug transport. As mentioned above, the 
hair follicles and associated sebaceous glands are considered to play a role with respect to 
transport across the skin; given that sebum consists mostly of neutral, non-polar lipids, it may 
be anticipated that this route favours more lipophilic permeants.  
  
The subcutaneous fat layer bridges between the dermis to the underlying tissue, and plays a 
negligible role in the percutaneous absorption of topically applied substances.  
    
1.3 Nanoemulsions 
 
1.3.1 Composition and preparation 
 
Nanoemulsions are stable dispersions with mean droplet diameters of a few hundred 
nanometers, and are sometimes called sub-micron or mini-emulsions. These systems are 
composed of oil, water, and one or more surface-active agents, and may be oil-in-water (o/w) 
or water-in-oil (w/o) dispersions [11]. In some circumstances, nanoemulsions may be formed 
using phospholipids as one of the surface-active constituents; if the level of lipid is high, the 
concurrent formulation of liposomes is possible [12]. The aqueous phase may contain 
hydrophilic, pharmaceutical or cosmetic active ingredients and preservatives, while the oil 
phase is typically composed of mineral oil, silicone oil, vegetable oil, esters of fatty acids, 
and/or lipophilic active ingredients. Surfactants, such as disodium stearoyl glutamate, sucrose 
alkyl ester, sorbitan alkyl ester and dimethicone copolyol, are added to the formulation to allow 
formation of a stable dispersion and guarantee an appropriate shelf life of the product.  
 
Both o/w and w/o nanoemulsions can be used in pharmaceutical preparations for topical 
administration. In the former case, the common oil core constituents are triglycerides, 
propylene glycol mono caprylic ester, cholesteryl esters and cholesterol [13]. Most 
nanoemulsions in cosmetics are oil-in-water and contain 10-20% oil stabilized with 0.5-2% 
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emulsifying agent. Popular oils are triglycerides, silicones, isopropyl myristate, isocetyl 
isostearate and isododecane. As well as conventional surfactants, polymeric emulsifiers, such 
as carbomers and hydroxypropyl methylcellulose (HPMC), are also being used to produce 
stable products with a pleasant appearance [14]. Carbomers are crosslinked polyacrylic acid 
polymers; and represent the most widely used gelling agents in skincare products [15]. Once 
introduced into a nanoemulsion, irregular structures on the order of a micron in size are 
observed (Figure 1.3), in proportion to the amount of carbomer employed. Carbomers can form 
a thick protective gel layer around each oil droplet and increase the viscosity of the external 
phase. Following contact with the skin, electrolytes from the skin surface cause the protective 
gel layer to deswell instantly. The oil phase is released and a thin film is deposited on the skin. 
This mechanism permits the convenient formulation of sun-care products which are ultimately 
waterproof despite their predominantly hydrophilic properties prior to application. The 
emulsification mechanism of HPMC is similar to that of carbomer, although the former is less 
sensitive to the presence of electrolytes. It is believed that the mechanical stress, imparted on 
application of these emulsions, causes a partial breakdown of their structures such that a thin 
film of oil spreads over the skin surface, reducing its wettability. After the water has 
evaporated, a flexible film remains consisting of oil droplets embedded into the polymer 
matrix [14].  
 
 
 
Figure 1.3: Image of a nanoemulsion (15% oil) stabilized with 0.2% carbomer at pH = 7. 
Adapted from reference [15].  
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Nanoemulsions are easily produced in large quantities by mixing a water-immiscible oil 
phase into an aqueous phase using a high-stress, mechanical extrusion process [16, 17]. 
 
1.3.2 Applications of nanoemulsions in pharmaceutics 
 
An o/w nanoemulsion containing 10% (m/m) oil (propylene glycol mono-caprylic ester and 
glycerol triacetate), 50% (m/m) surfactant (diethylene glycol monoethyl ether and Tween-80) 
and 40% (m/m) water has been suggested as a vehicle for the improved transdermal delivery of 
celecoxib [18]. In vitro skin permeation studies showed enhanced percutaneous uptake of the 
drug from the nanoemulsion relative to a simple gel [18]. In vivo, inhibition of 
carrageenan-induced paw edema in rats was observed when celecoxib nanoemulsion was used. 
The ability of nanoemulsion formulations to enhance topical drug delivery has also been 
shown for ketoprofen [19]. It was claimed that the drug permeation rate could be manipulated 
by changing the relative amounts of oil, surfactants and co-surfactants. Similarly, another study 
with an aceclofenac nanoemulsion showed improved permeation of the drug into rat abdominal 
skin, and significantly increased anti-inflammatory effect on carrageenan-induced paw edema 
in rats in vivo, when compared with a gel formulation [20].   
 
As well as acting as a drug carrier, nanoemulsions themselves have extensive antimicrobial 
activity against bacteria (e.g., E. coli, Salmonella, S. aureus), viruses (e.g., HIV, Herpes 
simplex), fungi (e.g., Candida, Dermatophytes), protozoa and spores (e.g., anthrax) due to their 
ability to fuse with and lyse these different organisms. Fusion is primarily driven by the 
electrostatic attraction between the typically cationic charge of the emulsion and the anionic 
charge on the pathogen. There is one example of the antimicrobial effects of surfactant 
nanoemulsions. A w/o nanoemulsion (X8W60PC), containing oil (64%), detergents (9.7%), 
solvent (8%) and water (18.3%), at a low concentration of 1%, significantly reduced the 
number of colony forming units (CFU) of Candida. albicans by more than four logs within 15 
minutes of treatment, and by six logs in a two-hour exposure. Because some of the ingredients 
of X8W60PC are biocidal, the anti-fungal activity of the individual ingredients was also 
evaluated at concentrations equivalent to those in X8W60PC. However, none of the constituents 
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was as effective a fungicidal as the nanoemulsion (Figure 1.4), suggesting that the activity of 
X8W60PC depends upon its nanoemulsion structure [21].   
 
 
 
Figure 1.4: The susceptibility of Candida albicans to a X8W60PC nanoemulsion and to its 
individual ingredients. Cells were treated with either 0.1% X8W60PC nanoemulsion or with 
individual ingredients at the equivalent concentrations for 15 minutes at 37°C. After treatment, 
cells were washed and plated on BH1 plates to assess the number of CFU. The bars represent 
standard error. D1, D2, and D3 depict three detergents used to prepare X8W60PC. Redrawn 
from reference [21].  
 
A special type of topical nanoemulsion has been developed for the instillation of an 
adrenergic β-blocking agent, adaprolol maleate, into the eye, to treat glaucoma without 
inducing systemic side-effects. However, the drug has an important clinical disadvantage of 
irritation to the eye, causing an immediate burning sensation and local discomfort. A 
nanoemulsion formulation, on the other hand, maintains the therapeutic efficacy of the drug 
while reducing the level of ocular irritation [13].  
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1.3.3 Applications of nanoemulsions in cosmetics 
 
The aesthetic properties of nanoemulsions, i.e., low viscosity and transparence with small 
droplet size, make them attractive for use in cosmetics products such as bath oils, body creams, 
anti-wrinkle and anti-aging preparations, and numerous patents reflect the active development 
of these formulations. For example, nanoemulsions containing fluid, non-ionic, amphiphilic 
lipids, such as diglyceryl isostearate, sorbitan oleate, and α-butylglucoside caprate, were stable 
on storage between 0°C and 45°C [22], were able to contain significant amounts of fragrance, 
and promoted the penetration of “actives” into the surface layers of the skin. Nanoemulsions 
made with anionic, amphiphilic lipids of phosphoric acid fatty esters and oxyethylenated 
derivatives also retained transparency and good cosmetic properties even when large amounts 
of oil were added to the formulations [23]. Another o/w nanoemulsion based on one or more 
nonionic and/or anionic amphiphilic lipids, and one or more water-soluble neutral polymers 
(e.g. poly-(ethylene oxide), polyvinyl alcohols; polyvinylcaprolactam), allowed the viscosity of 
the composition to be increased without influencing its transparency or increasing the level of 
the oil phase [24]. A stable and translucent nanoemulsion for cosmetic, dermatological and/or 
ophthalmological applications comprised a ternary surfactant system of ethoxylated fatty ester 
polymer, fatty acid ester of sorbitan and alkali metal salts of cetyl phosphate or palmitoyl 
sarcosinate, did not require gelling agents for stabilization [25], making it suitable for use on 
sensitive skin. Several other nanoemulsion technologies have been developed for diverse 
properties, including sun-protection, anti-wrinkling, anti-aging of the skin and other cosmetic 
targets [26-29]. 
 
1.3.4 Summary 
 
Nanoemulsions consist of fine o/w or w/o dispersions. They are used in dermatology to 
improve drug delivery to and through the stratum corneum. In addition, nanoemulsions 
themselves are biocidal towards bacteria, viruses, fungi, protozoa and spores. In cosmetics, 
nanoemulsions have found use in many cosmetic products for their transparent visual aspect, 
hydrating power and good skin feel.  
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1.4 Liposomes 
 
1.4.1 Composition and preparation 
 
Liposomes are spherical vesicles consisting of one or more membrane-like phospholipid 
bilayers enclosing an aqueous core. Vesicle diameter ranges from 50 to several hundred 
nanometers. The principal lipid component of liposomes is typically phosphatidylcholine (PC) 
derived from egg or soybean lecithin [30]. Cholesterol is usually included in the composition 
to stabilize the structure thereby generating more rigid liposomes [31]. Depending on the 
processing conditions and the chemical composition, small unilamellar vesicles (SUV), large 
unilamellar vesicles (LUV), large multilamellar vesicles (MLV) and multivesicular vesicles 
(MVV) may be formed with one or several concentric bilayers (Figure 1.5). Unlike emulsions, 
liposomes are thermodynamically stable lamellar structures which form spontaneously when 
lipid is brought into contact with an aqueous phase [32].   
 
 
Figure 1.5: Schematic illustration of liposomes of different size and number of lamellae. 
Redrawn from reference [14].  
 
Liposomes can be prepared by a number of methods. The major techniques are lipid film 
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hydration, emulsification, reverse phase evaporation, freeze-thaw processes, and solvent 
injection. Large liposomes form spontaneously when phospholipids are dispersed in water 
above their phase transition temperature. To prepare small vesicles, an appropriate technique, 
such as high-pressure homogenization, sonication, or extrusion, is required to reduce particle 
size. It should be stated that most of the methods for preparing liposomes have at least one of 
the following drawbacks: use of large quantities of solvent, need for special equipment, and 
low “active” encapsulation efficacy.  
 
Due to their biphasic character, liposomes can act as carriers for lipophilic, amphiphilic and 
hydrophilic substances. The entrapped compound’s solubility and partitioning characteristics 
will determine its location in the liposomal bilayer, its level of association with the liposome 
and its release rate. In general, lipophilic and amphiphilic substances, e.g., oil-soluble UV 
filters, are located in the lipid bilayer of the liposome. As such compounds are very poorly 
water-soluble, loss of entrapped drug on storage is minimal. Hydrophilic drugs are entrapped 
inside the aqueous core of liposomes, but may also be in the external water phase. The 
percentage of encapsulated hydrophilic drug depends on the liposome bilayer composition and 
the preparation procedure.  
 
1.4.2 Applications of liposomes in pharmaceutics 
 
The first report of the use of liposomes in topical drug delivery involved delivery of 
triamcinolone acetonide. It was claimed that the liposomal formulation significantly increased 
the concentration of steroid achieved in the epidermis and dermis [33]. In a further study, it 
was reported that application of triamcinolone acetonide-loaded liposomes resulted in ~5-fold 
more drug accumulation within the epidermis in comparison to a more conventional gel 
formulation [34]. A number of other studies have implied the efficiency of liposome 
formulations to deliver enhanced drug amounts to the upper skin layers. For example, a 
liposome formulation of betamethasone dipropionate out-performed a commercial 
conventional formulation containing a higher concentration of drug in a clinical trial 
considering the treatment of atopic eczema [35]. The liposome formulation was less efficient in 
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treating psoriasis for which deeper penetration of the drug is needed. Econazole, topical 
antifungal drug, can be irritant to the skin when topically applied in conventional vehicles. The 
application of liposome formulation has been shown to be a good strategy to minimize this 
irritation and enhance patient compliance. In biodisposition studies with a econazole in a 
liposomal gel dosage form, an ~7-fold increase in drug concentration in the epidermis was 
achieved, relative to a control cream [36]. It was possible, therefore, to reduce the applied drug 
dose yet maintain an equivalent therapeutic efficacy, thereby minimizing skin irritation. 
Similar results have been obtained with minoxidil, a drug to combat hair loss, and several 
liposomal products have been shown to be more efficient in delivering the drug to hair follicles 
than conventional dosage forms [36, 37]. Likewise, the local anesthetic agents, tetracaine and 
lidocaine, showed enhanced activity over conventional dermatological preparations when 
liposomal products were used [38, 39]. 
 
Of course, the efficiency of topical drug delivery from liposomal vehicles depends on the 
physicochemical properties of drug involved [40]. For example, the release of progesterone 
from Intralipid® emulsion was substantial, whereas egg-phosphatidylcholine and 
dipalmitoylphosphatidylcholine liposomal formulations delivered only 1% of the drug 
“payload” over a similar period [41]. The release of progesterone from liposomes followed 
zero-order kinetics, controlled by slow interfacial transport of the drug from the bilayer into the 
surrounding aqueous medium.  
 
When caffeine (3% w/v) was delivered from (i) an aqueous solution, (ii) a PEG solution, (iii) 
an aqueous solution containing the enhancers, transcutol and oleic acid, (iv) a PEG-water 
solution with the same enhancers, and (v) a phosphatidylcholine/cholesterol liposomal (SV) 
formulation, the results in Figure 1.6 were obtained [42]. Notably, the enhancers were effective, 
and interestingly the vesicles significantly retarded the delivery of caffeine. This resulted, after 
24 hours, in a much higher retention of the active in the epidermis following SV application. 
The same improved accumulation of drug in the skin has also been reported for a liposome 
formulation containing unfractionated heparin [43].  
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Figure 1.6: Effect of different formulations on the flux of caffeine through hairless mouse skin 
(3% caffeine in each system). Adapted from reference [42].  
 
The exact manner in which topical liposomes interact with the SC, and the lipids therein, is 
not fully characterized, especially when this occurs in the presence of an organic solvent, such 
as ethanol. Enhanced mixing with the intercellular lipids of the SC and/or the sebaceous lipid 
on the surface and within the hair follicles seems likely and logical. Microscopic observations 
have confirmed the fusion of liposomes on the SC surface resulting in stacks of lamellae and 
other, irregular structures [44]. It must be also remembered that the amount of lipid in the SC 
intercellular spaces may be small, relative to that applied in the form of liposomes. A square 
centimeter of SC of thickness of 10 µm has a volume of 1µl; given the “brick-and-mortar” 
structure of the SC, ~20% may be assumed to be associated with intercellular (and surface) 
lipid, which is 0.2 µl of lipid. Taking lipid density as about 1 g/ml (1 mg/µl), then the lipid 
content of 1 cm2 of SC is approximately 0.2 mg, an amount comparable to or smaller than the 
levels of lipid typically used when assessing the impact of formulations. It is perhaps not 
surprising, therefore, that enhanced deposition of drug into the SC is found when these 
preparations are used.  
 
1.4.3 Applications of liposomes in cosmetics 
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Liposomes are found in numerous products designed to deliver active cosmetic substances 
into the epidermis. The aim is to concentrate the active ingredients in the outermost skin layers. 
For example, liposome-encapsulated UV filters incorporated into aqueous-based sunscreens 
products have good substantivity on the skin surface, thereby preventing them from being 
easily washed off. Liposomes themselves, when formulated into cosmetics, can 
replenish/augment the endogenous SC lipids, increase moisturization and reduce skin dryness 
[45].  
 
There are many marketed liposomal cosmetics. Capture® was the first product incorporating 
liposomes and was introduced by C. Dior in 1986. It contains 5% thymus extract, 1% collagen 
and elastin peptides, and 0.1% hyaluronic acid in liposomes (100 nm diameter) made from 
soya lecithin [46]. Estée Lauder’s “Advanced Night Repair Protective Recovery Complex®” 
contains a liposome delivery system which is claimed to neutralize and repair 90% the damage 
caused by free radicals generated by UV, pollutants and oxidants. The formulation contains 
hyaluronic acid and is an effective moisturizer too. L'Oréal has pioneered the development of 
nanosomes (i.e., very small liposomes) in an anti-wrinkle product, “Revitalift® Double Lifting”, 
containing pro-retinol A [47]. Jafra Cosmetics International’s “Royal Jelly Lift Concentrate®” 
includes liposomes and a complex mixture of amino acids, vitamins and minerals, to stimulate 
cell renewal and prevent wrinkles [48]. Overall, cosmetic preparations containing liposomes 
range from simple creams and gels to complex formulations containing various extracts, 
moisturizers, antibiotics, and recombinant proteins for wound or sunburn healing. The 
commercial products are available as anti-aging skin creams, sunscreens, long-lasting 
perfumes, hair conditioners and so on.  
 
1.4.4 Summary 
 
The use of liposomes for the topical delivery of drugs and cosmetic actives represents a 
huge area of activity. The lipids comprising the vesicles clearly mix with endogenous SC lipids 
and transfer their encapsulated “payload” into the skin, sometimes undermining barrier 
function, at others providing reinforcement and improving hydration. Retention of an active at 
CHAPTER 1 
- 24 - 
the SC surface can also be achieved as a positive benefit (e.g., for a sunscreen). Many cosmetic 
products based on liposomes have reached the market.  
1.5 Transfersomes 
 
1.5.1 Composition and characteristics 
 
Transfersomes® (IDEA AG), are highly deformable mixed lipid aggregates, regarded as 
“elastic liposomes”. They differ from liposomes because of the presence of so-called 
edge-activators [49], and comprise phospholipids as the main ingredient with 10-25% 
surfactant (e.g. sodium cholate) and 3-10% ethanol. The surfactants are the “edge activators”, 
which confer ultradeformability on the transfersomes [50]. The elasticity of the vesicle is 
correlated with the quantity and the structure of the incorporated surfactant [51]. In comparison 
with liposomes, it has been claimed that transfersomes are able to deliver their “payload” 
deeper into the skin [35, 52].  
 
1.5.2 Interaction of transfersomes with the skin 
 
The proposed driving force for the putative penetration of transfersomes across the skin is 
the water activity gradient between the relatively dehydrated skin surface and the aqueous 
viable epidermis [53]. Hence, when a transfersome formulation is applied on the skin under 
non-occlusive conditions, the evaporation of water from the vehicle drives the penetration of 
vesicles towards the viable epidermis to avoid their dehydration [54]. It has been reported that 
transfersomes penetrate into the SC via two different hydrophilic pathways [55, 56]: (i) An 
intercluster route via the “gorge” between corneocytes clusters (formed by 3 to 10 individual 
corneocytes) which has a uniform width (≤ 4-6 µm) and depth (≤ 3-5 µm) (Figure 1.7); this 
pathway has a relatively low penetration resistance and corresponds to ≤ 1% of the total skin 
surface area. (ii) The intercorneocyte pathway travels between the individual corneocytes in 
the cell clusters, and occupies an area greater than 3% of the total skin surface area. 
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Figure 1.7: Left panel: laser scanning confocal microscopy image of nude mouse skin in vivo 
(~200 µm2 area). Right panel: Distribution of a fluorescent penetrant in the so-called 
intercluster (black) and intercorneocyte (grey) regions of the skin. Reprinted from reference 
[56].  
 
1.5.3 Applications of transfersomes in pharmaceutics 
 
The anti-inflammatory action of topical triamcinolone acetonide delivered from 
transfersomes was significantly greater than that induced by marketed products [57]. Moreover, 
the biological activity of the drug was maintained at doses at least one order of magnitude 
lower than that commonly used in commercial topical lotions or creams. As a result, it may be 
anticipated that any systemic side effects would be greatly reduced.  
 
It has also been reported that diclofenac associated with ultradeformable transfersomes is a 
good alternative for the combined oral and topical administration of the drug for rheumatoid 
disease [58]. Delivery from transfersomes sustained a prolonged therapeutic effect and resulted 
in a higher drug concentration in the skin than that from a commercial hydrogel. 
 
The topical administration of oestradiol from transfersomes and from rigid liposomes has 
been compared [59], and the deformable vesicles were shown to be significantly superior. This 
enhanced delivery was maintained for different “edge activators” [60]. Similarly, 
phosphatidylcholine vesicles containing sodium cholate, Span-80 or oleic acid significantly 
enhanced oestradiol transport across human skin in vitro relative to control formulations in 
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which the transfersome constituents were present, but had not been assembled into the 
ultradeformable particles [61]. Similarly, flexible liposomes containing cyclosporin A delivered 
more drug into the skin than conventional vesicles [62].  
 
Finally, and remarkably, transfersomes have also been claimed as a technology for the 
non-invasive delivery of insulin across the skin [63, 64], although the ultimate practicality of 
the approach remains to be established.  
 
1.5.4 Summary 
 
Transfersomes have been claimed to enhance significantly the local and systemic delivery 
of a wide range of compounds. The osmotic gradient across nonoccluded skin has been 
proposed as the driving force for this improved delivery when ultradeformable vesicles are 
used. Initial applications are focused upon non-steroidal anti-inflammatory drugs with a site of 
action beneath the skin in the subcutaneous tissue.   
 
1.6 Polymeric nanoparticles  
 
1.6.1 Nanocapsules 
  
1.6.1.1 Composition and preparation 
 
Polymeric nanocapsules are submicron colloidal particles with a core surrounded by a 
polymeric shell. In general, the core of nanocapsules is an organic (oil) solvent. Some of the 
most widely used polymers for the nanocapsule shell are poly-(ε-caprolactone) (PCL) [65], 
poly-L-lactide (PLA) [66], poly-(glycolic acid) (PGA), poly-(lactide-co-glycolide) (PLGA) 
[67], poly-(butylcyanoacrylates) [68-71], poly-(ethylcyanoacrylates) [72], poly-(alkylene 
adipate) [73], polyvinyl acetate (PVA) [74], cellulose acetate phthalate [75], 
poly-(ε-caprolactone)-block-poly-(ethylene glycol) [76], poly-(methyl methacrylate) [70], and 
polystyrene.   
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Methods for preparing nanocapsules can be classified into two categories. The first involves 
in situ interfacial polymerization around a droplet [77]; the second requires interfacial 
nanodeposition of a preformed polymers [78]. In interfacial polymerization, either a monomer, 
or an amphiphilic polymer with a cross-linkable group, is used and polymerization is induced 
at the surface of a droplet. A w/o or o/w emulsion is usually formed first before the shell is 
polymerized at the interface of two phases [79, 80]. This technique allows the polymeric shell 
to follow the contour of the inner phase. The drawback is that the polymerization process may 
provoke side-reactions involving the drug or active ingredient and reduce thereby their 
ultimate availability from the formulation. In preparing nanocapsules from preformed 
polymers, the deposition of the polymer at the surface of an oil droplet can be achieved by 
mixing the organic phase containing the polymer with an aqueous phase containing a 
hydrophilic surfactant. As the nanometer-sized droplets of oil form, the polymer precipitates at 
the interface with the aqueous phase and the nanocapsules are stabilized by the surfactant [81]. 
This technique avoids some of drawbacks of the interfacial polymerization process, such as 
lack of control of molecular weight, the presence of residual monomer in the preparation, and 
the possibility of side-reactions.  
 
1.6.1.2 Applications of nanocapsules 
 
Nanocapsules have been proposed as topical formulation constituents for several active 
compounds, including diclofenac, lidocaine, caffeine, retinoids, vitamin E, beta-carotene, 
amino acids, plant extracts, fragrances, antioxidants and UV protectants. The nanocapsule core 
has the advantage of providing a high loading capacity, with a relatively low polymer content. 
Compared to liposomes, polymeric nanocapsules are more robust as the shell is a covalently 
linked structure.  
1.6.1.2.1 Applications of nanocapsules in pharmaceutics 
 
The first polymeric particle system used for transdermal drug delivery comprised PLA 
microcapsules containing the contraceptive steroid, levonorgestrel [66]. Subsequently, 
indomethacin was encapsulated in poly-n-butylcyanoacrylate nanocapsules and improved the 
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transdermal delivery of the drug compared with a conventional gel [71]. Nanoencapsulation of 
flufenamic acid using PLGA nanocapsules also resulted in significantly increased drug 
accumulation in the viable skin layers when assessed in vitro using different experimental 
models [67]. Delivery of chlorhexidine from PCL nanocapsules synthesized by interfacial 
polymerization has been assessed on eight bacteria strains. Sustained drug release was 
achieved and a prolonged ex vivo topical antimicrobial activity on porcine ear skin against 
Staphylococcus epidermis was reported [82]. The improved efficacy was explained by a more 
direct and sustained contact between the particles, bacteria, skin surface and hair follicles. 
1.6.1.2.2 Applications of nanocapsules in cosmetics 
 
Generally, nanocapsules are used in cosmetics to protect sensitive actives, reduce 
undesirable odours and avoid incompatibility between formulation ingredients. One of the first 
nanocapsule-based products was an anti-wrinkle cream encapsulating vitamin A; the particles 
acted as reservoirs, slowly releasing the active over time [83]. Recently, L'Oréal marketed two 
products, Primordiale Intense and Hydra Zen Serum, which use nanocapsules to encapsulate 
several active ingredients.  
 
Nanocapsules have also been intensively investigated as sunscreen vehicles for octyl 
methoxycinnamate (OMC), octyl salicylate and benzophenone-3. It is believed that the 
nanocapsules form a protective film on the skin surface and retard any penetration of the active 
sunscreen into the viable tissue. For example, PCL has been used to prepare OMC-loaded 
nanocapsules which were more effective in protecting against UVB radiation than a 
conventional gel [65]. OMC was also encapsulated in cellulose acetate phthalate nanocapsules 
and its accumulation in the SC was compared to that from a nanoemulsion [75]. In this case, 
the nanocapsules were less efficient in delivering OMC. The encapsulation of benzophenone-3 
(oxybenzone) in a series of nanoparticles made from PVA-fatty acid (Figure 1.8) with different 
molecular weights has been reported [74]. The nanocapsules significantly decreased the 
transport of oxybenzone through porcine ear skin in vitro by more than an order of magnitude 
(Figure 1.9)   
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Figure 1.8: Chemical structure of PVA-FA derivatives. Redrawn from reference [74].  
 
 
 
Figure 1.9: Amount of benzophenone-3 absorbed across porcine ear skin in vitro (Mt), relative 
to the applied quantity (Mo), as a function of time following administration of various 
PVA-fatty acid nanocapsule-containing suspensions. The highest degree of transport occurred 
when the sunscreen was applied in solution in the absence of nanocapsules. Redrawn from 
reference [74].  
 
1.6.2 Nanospheres  
 
Nanospheres comprise a homogeneous matrix of polymer in which the drug or active 
ingredient is dispersed throughout. Generally, methods used to prepare nanospheres can also be 
adapted to the manufacture of nanospheres [77], i.e., interfacial polymerization, emulsion 
polymerization and solvent evaporation [11].   
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For example, the controlled release of captopril from poly-butylcyanoacrylate nanoparticles 
has been achieved, but improved skin transport was not observed [69]. Somewhat improved 
delivery of minoxidil from poly-(caprolactone)-block-poly-(ethylene glycol) nanoparticles was 
reported, with a better result achieved from that of smaller diameter (40 versus 130 nm) [76]. 
Further, cyclosporine A loaded into chitosan nanospheres better maintained an effective drug 
concentration on the ocular surface (for up to 48 hours) while avoiding systemic exposure, 
rapid clearance, eye irritation and blurred version [84]. 
 
1.6.3 Summary  
 
Polymeric nanoparticles are unable to cross intact SC. Drugs incorporated into 
nanoparticles may be slowly released onto the skin surface and into the superficial skin strata. 
Nanoparticles incorporated in cosmetic preparations can protect unstable active ingredients, 
avoid incompatibility between different ingredients, and ensure that the absorption of 
sunscreens, for example, is avoided by forming a film on the skin surface. However, the 
number of products on the market that are based on polymeric nanoparticles is limited. This is 
due to a number of factors including the cytotoxicity of some polymers, and problems of 
scaling up the complex preparation methods involved.  
 
1.7 Solid lipid nanoparticles (SLN) 
 
1.7.1 Composition and preparation 
 
SLN are sub-micrometer in size [85, 86]. The lipids employed include triglycerides, partial 
glycerides, fatty acids, steroids and wax. Different emulsifiers have been utilized to stabilize 
SLN dispersions, including Poloxamer 188, Polysorbate 80, lecithin, polyglycerol 
methylglucose distearate, sodium cocoamphoacetate and saccharose fatty acid esters [87].  
 
The two principal SLN preparation methods are high pressure homogenization and via 
microemulsion formation. The former is subdivided into hot and cold techniques [86, 88-91]. 
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Hot homogenization is the most frequently used. In this method, the lipid melt is dispersed in a 
hot surfactant solution at the same temperature by high-speed stirring. The resulting 
pre-emulsion is passed through a high pressure homogenizer to produce a hot o/w 
nanoemulsion. The lipid recrystallizes to SLN as the hot nanoemulsion is cooled to room 
temperature. It is noteworthy that for lipids (e.g., glycerides) with a low melting point close to 
room temperature, the nanoemulsion needs to be cooled to even lower temperatures to initiate 
recrystallization. The hot homogenization method may be suitable for temperature-sensitive 
compounds, because the time of exposure to an elevated temperature is relatively short [86].  
 
The cold homogenization technique is recommended for preparing SLN containing either 
highly temperature-sensitive compounds or hydrophilic compounds which can partition from 
the melted lipid phase to the water during a hot homogenization process [88]. In the cold 
homogenization technique, the melted lipid containing the drug is cooled, and then ground to 
microparticles which are subsequently dissolved in a cold surfactant solution to form a 
pre-emulsion. This is then homogenized into SLN at or below room temperature. As 
homogenization can cause an increase in temperature, the difference between the lipid melting 
point and the homogenization temperature should be large enough to avoid melting of lipid in 
the homogenizer.  
 
When SLN are produced by the microemulsion technique, the melted lipid and the aqueous 
surfactant solution must be at the same temperature. Surfactants and co-surfactants used 
include lecithin, bile salts and alcohols such as butanol. The two phases are mixed in the 
correct ratio to form a microemulsion, which is then dispersed in a cold aqueous medium 
(2-3°C) under gentle mechanical mixing, to ensure that small particles are formed by 
precipitation [92].  
 
SLN can be also produced by a precipitation method [93]. The lipid is dissolved in an 
organic solvent and an aqueous phase is added provoking emulsification [94]. The solvent is 
then evaporated and the lipid precipitates forming nanoparticles. A disadvantage of this method 
is the use of organic solvent.  
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1.7.2 Applications of SLN in pharmaceutics 
 
SLN have been used to enhance the topical delivery of several drugs. For example, SLN 
containing tristearin glyceride, soybean lecithin and polyethylene glycol 400 stearate increased 
the transport of triptolide in vitro by 3 to 4-fold over that from a simple solution of the drug 
[95]. In eczema patients, SLN loaded with clobetasol propionate showed improved efficacy 
over a conventional cream [96]. Prednicarbate associated with SLN (again for eczema 
treatment) was better delivered to the viable epidermis, with less exposure to (and atrophy of) 
the underlying dermis [90, 97], suggesting a possible targeting effect. Antiandrogens for acne 
treatment have also been shown to have better efficacy when topically applied in SLN 
formulations [98]. Once again, drug was concentrated in the outer skin layer and deeper 
penetration to underlying tissues and to the systemic circulation would be expected to be 
minimal. It was also shown that the lipophilic fluorescent marker, Nile Red, was delivered 
from the SLN to the hair follicle infundibulum, once more implying an ability to target a 
specific skin structure.  
   
1.7.3 Applications of SLN in cosmetics 
 
After topical application, SLN can form an occlusive adhesive film on the skin surface 
[99-103]. For example, an SLN formulation containing tocopherol acetate was twice as 
occlusive as an emulsion with identical lipid content (Figure 1.10) [100]. Scanning electron 
microscopy was used to visualize the SLN on a single tape, and showed complete film 
formation without distinguishing individual particles (Figure 1.11).  
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Figure 1.10: Relative occlusivity of tocopherol acetate-based SLN and a reference emulsion 
after 6, 24 and 40 h post-application. Redrawn from reference [100].  
 
 
 
Figure 1.11: Scanning electron micrograph of a dried SLN film on a single tape. Reprinted 
from reference [100].  
 
SLN appear quite attractive as components for sunscreen products. Not only does the lipid 
matrix at the skin surface retard the penetration of the active, molecular UV absorbers 
themselves (thereby reducing potential toxicity relative to conventional formulations) [88, 100, 
104-107], the SLN on their own have a sun-protective effect by efficiently scattering the 
radiation falling on the skin (similar to titanium dioxide particles [108]). Cetyl palmitate SLN 
containing molecular sunscreens have been shown to have this synergistic photoprotection 
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effect [88, 100, 105, 108].  
 
Moreover, incorporation of chemically labile active ingredients (e.g., coenzyme Q10, retinol, 
and tocopherol) into SLN offers protection against decomposition [109-114] and, finally, it 
should be mentioned that the controlled release of an active ingredient is possible from SLN 
either to provide a burst release or a more sustained delivery profile [104]. This feature has 
been exploited for the controlled release of retinol and oxybenzone from SLN incorporated 
into creams and hydrogels [105, 112].   
 
1.7.4 Summary 
 
SLN have formed a wide range of applications and have useful properties for maintaining 
“actives” on the SC surface or within the upper skin layers. Their ability to form adhesive, 
occlusive films is particularly useful for sunscreen applications and for maintaining the 
stability of labile chemicals.  
1.8 Ethosomes 
 
1.8.1 Composition and characteristics  
 
Ethosome are primarily composed of phospholipids, relatively high concentrations of 
ethanol, and water [115-118]. Their average diameter ranges from tens of nanometers to 
microns, and depends upon the relative amounts of phospholipids and ethanol [115]. Similar to 
liposomes, ethosomes can be unilamellar [119, 120] or multilamellar [115, 116, 121].  
 
A number of methods have been used to prepare stable ethosomal formulations depending 
on the drug characteristics and on the drug delivery target [117, 118]. The manufacturing 
processes are easily scaled-up. The presence of ethanol allows for efficient entrapment of 
hydrophilic, lipophilic and amphiphilic molecules. This feature is illustrated by research in 
which three fluorescent probes of distinct physicochemical properties were encapsulated in 
ethosomes and liposomes, and their behaviour was then examined by laser scanning confocal 
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microscopy (LSCM) [115]. The three dyes were the lipophilic Rhodamine Red, 
dihexadecanoyl glycerophosphoethanolamine (RR), the amphiphilic 4-(4-diethylamino) 
styryl-N-methylpyridinium iodide (D-289), and the hydrophilic calcein. Figure 1.12 shows that 
the lipophilic and amphiphilic drugs were clearly associated with the liposomal bilayer, while 
calcein was concentrated in the aqueous core. In contrast, all the dyes were found throughout 
the entire volume of the ethosomes at high apparent loading.  
 
 
 
Figure 1.12: Entrapment of three fluorescent probes by liposomes (a-c) and ethosomes (d-f). 
The fluorescent probes were rhodamine red (a, d), D-289 (b, e) and calcein (e, f). White 
represents the highest concentration of probe, with yellow and red signifying progressively 
lower levels. Reprinted from reference [115].  
 
1.8.2 Enhanced transdermal drug delivery from ethosomes  
 
It is claimed that ethosomes significantly enhance drug delivery across the skin by two 
principal mechanisms: (a) a fluidizing effect of ethanol on phospholipid bilayers creating a 
“soft”, deformable vesicle [115, 119-121], and (b) SC lipid disruption by ethanol thereby 
permitting entry of ethosomes and their associated “payload” into the deeper skin layers 
(Figure 1.13) [115].  
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Figure 1.13: Proposed mechanisms for enhanced drug delivery across the skin from ethosomal 
vehicles. Adapted from reference [115].  
 
Delivery of the three aforementioned fluorescent probes into nude mouse skin from 
ethosomes, liposomes and a hydroalcoholic solution was assessed by LSCM. For both 
rhodamine red and D-289, optical sectioning of the skin after an 8-hour application clearly 
demonstrated that ethosomes were the superior delivery system (Figures 1.14 and 1.15). 
Uptake from the hydroalcoholic solution was greater than that from the liposomes employed. 
Quantitative analysis of the fluorescence intensity as a function of the depth again revealed the 
superiority of the ethosomal formulation, in this instance, for calcein and rhodamine red 
(Figure 1.16). 
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Figure 1.14: LSCM images of rhodamine red penetration into nude mouse skin following an 8 hour application of (a) ethosomes, (b) a hydroalcoholic 
solution of the dye, and (c) liposomes. Reprinted from reference [115]. 
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Figure 1.15: LSCM images of D-289 penetration into nude mouse skin following an 8-hour application of (a) liposomes, (b) a hydroalcoholic solution of the 
dye, and (c) ethosomes. Reprinted from reference [119]. 
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Figure 1.16: Skin penetration profiles of (A) calcein, and (B) rhodamine red, following their 
application to hairless mouse skin from either ethosomes, liposomes or a hydroethanolic 
solution for 8 hours. Depth of skin penetration and fluorescence intensity were determined by 
LSCM. Significantly different values (*p<0.001, **p<0.05; ethosomes versus other systems) 
are highlighted. Redrawn from reference [122].  
 
Anti-infective drugs when associated with ethosomes appear to be much more efficient 
delivery systems than classic liposomes. For instance, fluorescently-labeled bacitracin, a 
polypeptide antibiotic, was delivered from ethosomes to a depth of 200 µm in dermatomed 
human cadaver skin, whereas its delivery from classic liposomes was negligible [121]. Another 
study with ethosomal erythromycin demonstrated an improved antibacterial action in 
comparison to a hydroethanolic solution of the drug. Moreover, an infected skin site treated 
with the topically applied ethosomal formulation healed as well as that achieved when the drug 
was systemically injected [123].  
CHAPTER 1 
- 40 - 
 
Other examples of the efficacy of ethosomal vehicles can be mentioned. Pretreatment of the 
skin with a formulation containing ammonium glycyrrhizinate (AG), a natural 
anti-inflammatory agent effective in acute and chronic dermatitis, significantly reduced the 
intensity and duration of methyl nicotinate-induced erythema in healthy human volunteers, 
compared to hydroalcoholic solutions of the drug [124].  
 
Ethosomes have also been reported to enhance the percutaneous delivery of ionized drugs, 
very lipophilic compounds and large hydrophilic molecules. For example, the flux of 
trihexylphenidyl hydrochloride, an anti-Parkinsonian agent, from an ethosomal vehicle was 
substantially higher than that from liposomes [119]. Similar results have been reported for 
propranolol hydrochloride and sodium diclofenac [117]. Ethosomal formulations of 
testosterone have been compared with marketed transdermal patches, and shown to achieve 
significantly higher AUC and Cmax values [115, 125]. Finally, when acyclovir (an effective 
antiviral drug for the treatment of recurrent herpes labialis infection) was formulated in 
ethosomes, its delivery resulted in a marked improvement in therapeutic efficiency, compared 
to the normal treatment (Zovirax® cream), presumably as a result of the improved penetration 
of the active from the lipid-ethanol vehicle [126].   
 
1.8.3 Summary 
 
Ethosomes have recorded some notable improvements in topical and even transdermal drug 
delivery. While the precise mechanisms of action remain less than fully clear, the combination 
of a relatively high “dose” of exogenous lipid and ethanol can cause perturbation of SC barrier 
function. Whether this approach will ultimately make a significant impact in the clinic requires 
considerable further work.  
 
1.9 Niosomes 
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1.9.1 Composition and preparation 
 
Niosomes are vesicles prepared from non-ionic surfactants, such as polyoxyethylene alkyl 
ethers, sorbitan esters, polysorbate-cholesterol mixtures, crown ethers, perfluoroalkyl 
surfactants, alkyl glycerol ethers, and others [127-131]. The surfactants combine one or more 
hydrophobic components (e.g., alkyls (C12-C18) or perfluoroalkyls (C10) or a steroidal group) 
with a hydrophilic head group (e.g., ethylene oxide, glycerol, crown ether, polyhydroxyls, and 
sugars). The hydrophilic and hydrophobic moieties are linked by ether, ester, or amide bonds.  
 
Niosomes are prepared by similar methods to those used for liposomes, such as hydration of 
a deposited surfactant/lipid film. This process is usually followed by homogenization, 
sonication, or extrusion to reduce vesicle size, and then separation of the un-entrapped drug 
[127, 128, 130]. The stability of niosomal formulations is influenced by factors such as storage 
temperature, preparation technique, and composition [127, 130]. Vesicle aggregation may be 
prevented by co-formulation with surfactants. Like liposomes, niosomes can form unilamellar 
or multilamellar structures, and have the further advantages of improved stability, high purity 
and low cost.  
 
1.9.2 Interaction of niosomes with the skin 
 
The interactions of niosomes with the SC have been studied using microscopic techniques. 
The presence of vesicular structures on or near the surface are clearly seen, but this 
concentration is quickly attenuated as one examines (e.g., with sequential tape-stripping) the 
deeper SC layer [132]. The implication is that the niosomes have fused and mixed with the 
endogenous SC lipids at this point [133, 134]. Although some images of vesicular structures at 
even deeper regions of the SC have been published, it is impossible to say whether these really 
represent intact niosomes which have transported down from the skin surface, or whether there 
has been spontaneous regeneration of a vesicle as the degree of hydration of the SC increases.    
 
1.9.3 Applications of niosomes in pharmaceutics and cosmetics 
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Drugs encapsulated in niosomes, when these vesicles fuse with the SC, may be subjected to 
enhanced skin penetration due to an altered thermodynamic activity gradient [133, 134], or to 
the action of the “released” nonionic surfactants on SC barrier function [134, 135]. Enoxacin, 
for example, was much better delivered from niosomes than either liposomes or when applied 
as a simple drug solution [133]. If niosomes are used on skin for which the barrier function is 
significantly less than that typical of intact skin, then even rather large compounds can be 
delivered. Thus, β-galactosidase and luciferase reporter genes have been successfully 
transported across rat pup skin from niosome formulations [136]. In addition, and similar to 
other vesicular carriers, niosomes have been shown capable of drug delivery to hair follicles, 
with successful results reported for the polypeptides, interferon-α and cyclosporine [137], as 
well as for minoxidil [138]. From a transdermal standpoint, estradiol has been examined and 
the nature of the surfactant used to prepare the niosomes clearly has an important effect [139, 
140]. Finally, niosomes have been incorporated into cosmetics for several years, and used in a 
manner not particularly different from liposomes [141].  
 
1.9.4 Summary 
 
  The behaviour and applications of niosomes parallel, in large part, those described for 
liposomes, although the level of activity, overall, is rather less.  
 
1.10 Conclusions 
 
Research into nano-sized delivery systems for topical “actives” has been the focus of 
considerable effort in the pharmaceutical and cosmetic industries for more than twenty years. 
The composition of different nanoparticles and their methods of preparation show some 
diversity. However, a size-reduction step with high pressure homogenization, sonication or 
extrusion is usually required to break some sort of microemulsion into nanoparticles. 
Depending on their intended use, the resulting carriers can be designed to facilitate or to retard 
the penetration of drugs and active ingredients into the epidermis or deep dermis and beyond. 
Rigid nanoparticles, such as liposomes, polymeric nanocapsules and SLN, improve 
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localization of the “active” in the upper skin layers, and may have an ability to form a skin 
surface film after topical application, thereby preventing water evaporation and increasing skin 
hydration. Transfersomes and ethosomes are variations of liposomes which incorporate “edge 
activators” or ethanol to confer the property of ultradeformability. It is claimed that this allows 
significantly enhanced transport of associated active species into the deeper skin layers via a 
variety of (not unambiguously proven) mechanisms, including an action as true “carriers”, SC 
lipid disruption, osmotic gradients, and so on.  
 
There is also a general perception that just about all nano-carriers can “target” appendagal 
structures, like hair follicles. However, it seems likely that this is a non-specific, physical 
phenomenon and it remains to be seen whether these observations can be translated into a real, 
observable benefit.  
 
In conclusion, despite a large and growing scientific and patent literature on the 
development and evaluation of nanoparticles for the delivery of topical agents, only a few 
commercial products containing such structures have appeared on the market. While the 
cosmetic industry has been quick to seize on these novel nanostructures, and to exploit their 
marketing and sensorial attributes, the pharmaceutical sector has been more reticent and has 
(currently) demanded quantifiable evidence that these inevitably more expensive products in 
terms of both materials and manufacture out-perform significantly more conventional 
formulations. For the moment, at least, this challenge has rarely been met.    
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Abstract  
   The influence of particle size and polymer properties on the topical delivery of a lipophilic 
“active” species from polymeric nanoparticles and mesoparticles was investigated. The 
formulations were prepared using a mini-emulsion/solvent evaporation technique and the 
fluorophore, Nile Red (NR), acting as a model for a lipophilic drug, was associated with the 
polymeric vectors. Three poly-(ε-caprolactone) (CAPA) formulations, with mean diameters of 90 
nm, 260 nm and 630 nm, were examined to assess the impact of particle size. Three other NP 
formulations (diameter ~100 nm), based on cellulose acetate butyrate (CAB), CAPA and 
polystyrene (PS) were studied to address the role of polymer hydrophobicity. The association of 
NR with the different particles was measured by ultracentrifugation. In vitro skin permeation 
experiments were performed for 6 hours, and confocal microscopy and tape-stripping of the 
stratum corneum (SC) were used to evaluate the disposition of NR in the skin. The SC 
concentration profiles of NR were influenced by nanoparticle size, with delivery being greater 
from the larger vectors, probably due to the overall smaller surface area of these particles 
enhancing the “leaving tendency” of the lipophilic “active”. The skin uptake of NR from PS, 
CAPA and CAB nanoparticles decreased, in absolute terms, with decreasing polymer 
hydrophobicity (PS>CAPA>CAB). However, given the degree to which NR was associated with 
the different particles, the relative “%payload released” actually increased as the polymer 
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hydrophobicity decreased (in a manner exactly as expected for a lipophilic moiety like NR). 
Confocal microscopy revealed that NR released from nanoparticles accumulated in, and penetrated 
via, the lipid domains between the corneocytes of the SC; furthermore, there was evidence that the 
particles themselves showed affinity for, and concentration at, the openings of hair follicles.  
 
Keywords: skin; stratum corneum; nanoparticle; Nile Red; particle size; tape-stripping; laser 
scanning confocal microscopy (LSCM).  
 
2.1 Introduction 
 
  The development of nanotechnology, and the increasing presence of nanoparticles (and other 
nano-structures) in pharmaceutical and cosmetic formulations designed for application to the skin 
[1-7], makes it essential to develop techniques to assess the local disposition of these materials.  
Although the principal function of the skin is to provide a protective barrier (a job that it performs 
remarkably well) [8-10], it is nevertheless important to determine whether nanostructures can find 
their way into and/or across this tissue, or whether they show a particular affinity, for example, to 
specific skin components such as hairs and the follicles from which hairs emerge. 
 
  A number of fundamental questions must therefore be addressed. For example, what happens to 
nanoparticles when they contact the skin? What is the disposition of the nanoparticles, and what is 
their residence time? It is necessary, therefore, to visualize nanoparticle disposition on and within 
the skin, to explore whether penetration pathways exist, and to examine the “substantivity” of the 
nanostructures to the membrane. Further, is there evidence that nanoparticles can cross the skin's 
barrier, the stratum corneum (SC)? Do nanoparticles show affinity for specific skin structures, e.g., 
hair follicles? Microscopic techniques and adhesive tape-stripping procedures can be used to 
address these issues qualitatively and quantitatively. Finally, to what extent does nanoparticle 
disposition depend on the properties of the particles (such as size and composition)? What happens 
to “active” species (e.g., drugs, cosmetic actives) which are associated with nanoparticles? 
 
  This paper addresses these latter issues, and explores the manner in which nanoparticle size and 
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polymer hydrophobicity influence the cutaneous disposition of a model, lipophilic compound 
associated with various “vectors”. Uptake into the skin’s outermost layer, the SC, has been 
determined by a validated and quantitative adhesive tape-stripping methodology and has been 
visualised by confocal microscopy. 
 
2.2 Materials and methods 
 
2.2.1 Materials 
 
2.2.1.1 Chemicals  
 
Poly-(ε-caprolactone) (CAPA 6100, Solvay, Paris, France), cellulose acetate butyrate 
(CAB-551-0.01, Eastman, Capelle aan den IJssel, the Netherlands), polystyrene (18544, 
PolySciences, Eppelheim, Germany), phenonip (Nipa, Clariant, Charlotte, NC, USA), pluronic 
F127 (Sigma-Aldrich, CHEMIE GmbH, Steinhelm, Germany), Nile Red (Analytical grade, 
Sigma-Aldrich, St. Louis, MO, USA), dichloromethane (99% Acros Organics, Loughborough, 
UK), acetonitrile (HPLC grade, Fisher Scientific Corporation, Loughborough, UK), ruthenium 
tetroxide (Taab Laboratories, Aldermaston, England), uranyl acetate (Agar Scientific Ltd. Stansted, 
UK). 
 
2.2.1.2 Skin tissues 
 
Full thickness porcine skin was obtained from a local slaughterhouse. The skin was cleaned 
under cold running water. The subcutaneous fat was removed from the skin with a scalpel. The 
remaining tissue was then dermatomed to a thickness of ~750 µm and was stored frozen at -20°C 
for up to a maximum of one month before use.  
 
2.2.2 Methods 
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2.2.2.1 Nano/mesoparticle preparation 
 
Nano/mesoparticles were prepared in the presence of the model “active”, Nile Red (NR), a 
lipophilic fluorophore, by a mini-emulsion/solvent evaporation method [11]. 1.25 g polymer, 0.3 g 
dimethicone copolyol and 1.25 mg Nile Red were dissolved in 17 ml dichloromethane, to form the 
organic phase. 0.125 g Pluronic F127 was dissolved in 25 ml water by vigorously stirring the 
mixture at 40°C for 30 minutes to provide the aqueous phase. The phases were then quickly mixed 
and dispersed under ultrasound (Ultra turrax® T25), 4°C. The resulting nanosphere pre-emulsion 
had a milky appearance with pink opalescence. Ultrasound at maximal power intensity for 5 
minutes was then used to break the pre-emulsion into fine nanoparticles. Finally, the organic 
solvent (dichloromethane) and some of the water present were removed by rotary evaporation. 
Phenonip was added into the emulsion as a preservative.  
 
2.2.2.2 Size distribution measurement 
 
The mean size and polydispersity (index from 0 to 1) of the NP were measured with dynamic 
light scattering (DLS BI90Plus, Brookhaven Instruments Corporation, NY, USA). Measurements 
were made in triplicate for all prepared batches. DLS is an instrument which determines the size 
distribution of particles by measuring dynamic fluctuations of light scattering intensity caused by 
the Brownian motion of the particle. This technique yields a hydrodynamic diameter that is 
calculated via the Stokes-Einstein equation from the aforementioned measurements. The DLS 
measures the average hydrodynamic diameter of the particles, the peak values in the 
hydrodynamic diameter distribution and the polydispersity index (PI) that describes the width of 
the particle size distribution. The PI scale ranges from 0 to 1, with 0 meaning that the size 
approaches a monoparticle size distribution and 1 indicating large variations in the particle size 
distribution.  
 
2.2.2.3 Assessment of Nile Red incorporation and HPLC assay 
 
To determine the degree of Nile Red incorporation into the nanoparticles, the formulations 
were filtered (0.45 µm nylon filters, Whatman, Japan) and then subjected to ultracentrifugation 
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at 17000 g for 3 h at 20°C. The supernatant was kept for analysis of NR. The sediment was 
washed with distilled water to remove surfactant and again centrifuged 17000 g for 3 h. The 
resulting pellet was freeze-dried, and then dissolved in dichloromethane. Finally, Nile Red in 
this organic solvent was measured by HPLC (Dionex, Sunnyvale, CA, USA) with fluorescence 
detection at 559 nm and 630 nm for excitation and emission wavelengths, respectively. A 
Hypersil BDS C18 (5 µm) 250×4.6 mm column, was used and the mobile phase was 
dichloromethane pumped at a flow rate of 1 ml/min at 25°C. Each injection was 200 µl of 
solution. The Nile Red retention time was 5.6 minutes. Nile Red in the supernatant was also 
measured by HPLC using a mobile phase comprising acetonitrile-water (80:20). The column, 
injection volume, temperature were as above. The retention time in this case was 12.1 minutes. 
 
2.2.2.4 In vitro skin permeation  
 
  Each skin sample used in these experiments represented one-half of a larger piece of tissue.  
The other portion was reserved for a determination of the SC thickness as described below. 
 
Visible hairs on the skin were trimmed as closely as possible to the surface. Skin permeation 
experiments were performed in vertical Franz diffusion cells thermostatted at 37°C. The 
excised tissue was clamped between the donor and receptor compartments exposing a 
diffusion area of 3.8 cm2. The receptor phase was physiological buffer (pH = 7.4); the donor 
compartment held 1 ml of the NP formulation and was covered with Parafilm. After an 
application lasting 6 hrs, the cell was dismantled, and the skin was immediately either 
examined by confocal microscopy or tape-stripped to determine the NR concentration profile 
across the SC. 
 
2.2.2.5 SC tape-stripping 
 
A validated tape-stripping procedure was used to assess the depth of NR penetration into the 
SC and recover NR from the treated skin. About 20 pieces of 2.7×2.7 cm square tapes were 
prepared using transparent Scotch® No.845 Book Tapes (3M Media, Broken, Germany). To 
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delimit a fixed area for tape stripping, a 5×5 cm square mask was prepared with a cut central 
aperture of 2 cm in diameter. A strip of adhesive tape was pressed firmly onto the skin surface, 
and then removed in a single movement. The direction of stripping was changed with each tape 
to ensure a more uniform removal of the SC with fewer tape-strips. Before and after each 
tape-strip, transepidermal water loss (TEWL) across the skin was measured with an Aquaflux 
device (Biox Systems Ltd., London, UK) to provide an idea of when most of the SC had been 
removed and to the end of the tape-stripping process. This was considered appropriate when 
TEWL reached 80 g-1m-2h. The tapes were weighed before and after stripping to determine the 
mass of SC removed. As the density of the tissue is ~1 g/cm3 [12, 13], the volume of SC 
removed by each strip is known assuming uniform coverage of SC on the tape-strip [12]. Then, 
given that the area stripped is kept at known, constant value, the thickness of SC removed as 
tape-stripping proceeds can be found.  
 
NR was extracted from the SC on the adhesive tapes by immersion in acetonitrile and 
shaking for at least 12 hrs. The extract was filtered (Whatman PTFE filter 0.45µm) into HPLC 
vials and analysed. The mobile phase was 80:20 v/v acetonitrile and water. All other HPLC 
conditions were as stated above. The limits of detection and quantification were 0.34 ng/ml 
and 1.16 ng/ml, respectively. 
 
2.2.2.6 SC thickness determination  
 
To calculate the total thickness of the SC, the same tape-stripping procedure was performed 
on the second of the skin sample with measurements of TEWL after each tape-strip [12]. The 
amount of SC removed on each tape was again determined gravimetrically and converted into 
a SC thickness removed on each strip. It was then possible to calculate the total thickness of 
the SC from the x-intercept of a graph of TEWL-1 versus the cumulative thickness of SC 
removed [12]. Knowing the SC thickness of each skin used in the NR uptake experiments 
made it possible to express all concentration profiles of the “active” as a common function of 
the relative position (depth) into the SC, greatly facilitating objective comparison of the results 
[14, 15].    
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2.2.2.7 Laser scanning confocal microscopy (LSCM)  
 
The treated skin was cleaned carefully with physiological buffer and dried with tissue. The 
skin was examined using a LSM 510 Invert Laser Scanning Microscope (Carl Zeiss, Jena, 
Germany). The system was equipped with both an argon laser (excitation line at 488 nm) and a 
HeNe laser (excitation line at 543 nm). A Plan-Neofluar 10×/0.3 objective, an EC 
Plan-Neofluar 40×/1.30 oil DIC M27 objective and a Plan-Apochromat 63×/1.40 oil DIC M27 
objective were used. Confocal images were obtained in the plane parallel to the sample surface 
(xy-mode), or in the plane perpendicular (optical sectioning z-stack mode). 
 
2.3 Results and discussion  
 
2.3.1 Nile Red association with nano/mesoparticles 
 
The quantities of NR incorporated into the particles, together with information on their size 
and polydispersities are summarized in Table 2.1. Uptake into the nano/mesoparticles made 
from CAPA was quite constant (46-49%). More NR was taken up into the hydrophobic PS 
particles (~77%), less into the more hydrophilic CAB formulation (~24%). A relatively 
constant amount of Nile Red was recovered in the supernatant for all nanoparticles, and it is 
inferred that the remaining fraction of the dye was associated with surfactant micelles. 
 
Table 2.1: Properties of nano/mesoparticle formulations examined. 
Nanoparticle formulation  
Average 
diameter (nm)
Polydispersity 
Index 
% Nile Red 
associated 
% Nile Red in 
supernatant 
CAPA NP I 90 0.172 46.3 ± 1.1 5.8 ± 0.2 
CAPA NP II 260 0.108 48.0 ± 1.6 5.8 ± 0.4 
CAPA NP III  630 0.116 48.6 ± 0.8 5.8 ± 0.3 
PS 156 0.098 76.9 ± 2.0 5.8 ± 0.4 
CAPA 148 0.133 48.6 ± 0.5 5.8 ± 0.3 
CAB 93 0.125 23.9 ± 1.5 5.8 ± 0.4 
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2.3.2 SC thickness determination  
 
Figure 2.1 shows typical results from the experiments conducted to determine SC thickness 
of the skin samples used in the NR uptake measurements. The variability between different 
skins is clear, and it was generally observed that SC on the abdomen of the pig was thinner 
than that on the dorsal surface (6.9 ± 0.8 µm versus 10.2 ± 1.7 µm, respectively, for the 
examples in Figure 2.1 (mean ± SD, n=3)). These results emphasize the value of the 
determination of SC thickness when the disposition of an “active” across the barrier is to be 
evaluated, as it means that all concentrations can be expressed on a common scale of SC 
penetration depth normalized by the total membrane width (see below). 
 
Figure 2.1: Illustrative experimental data for the determination of SC thickness (obtained from 
the x-axis intercepts of the above plots). Results in panel (a) were from dorsal skin samples, 
those in panel (b) from the abdomen. 
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2.3.3 NR concentration profiles across the SC 
 
In all experiments, independent of the formulation used, no fluorescence from NR was ever 
detected in the receptor phase, an observation consistent with earlier work [16, 17]. 
 
The SC concentration profiles of Nile Red delivered from the CAPA nano/mesoparticles of 
different average diameters are in Figure 2.2. From the measurements of TEWL and of the SC 
mass removed on each tape, the concentrations could be expressed as a function of relative 
position within the SC (as reported before [15]), thereby correcting for differences in absolute 
SC thickness from one porcine skin sample to another. The effectiveness of this strategy is 
reflected in the excellent reproducibility in the results obtained.  
 
 
 
Figure 2.2: SC concentration profiles of NR following a 6-hour application of CAPA 
nano/mesoparticles having mean diameters of 90 nm, 260 nm and 630 nm (n = 5; mean ± SD).  
Note that, on the x-axis, 0 indicates the SC surface, 1 reflects the SC-stratum granulosum 
interface. 
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NR was more efficiently transferred into the SC from the nano/meso-carriers as the particle 
size increased. The total amounts of NR delivered into the SC from the 90 nm, 260 nm, and 
630 nm formulations were 0.023, 0.033, and 0.058 µg, respectively. As the precise localization 
of NR in the CAPA nano/mesoparticles is not known, an unambiguous explanation for the 
observations is not possible. However, if, as suspected, NR is predominantly absorbed onto the 
particle surface, then the larger carriers obviously offer a smaller surface area and the “leaving 
tendency” of NR from the vehicle would be enhanced. Furthermore, the larger particles have 
bigger contact areas with the surface of SC than the smaller particles, which could be also 
facilitate the partition of NR from their vehicles into the SC (Figure 2.3).  
 
 
Figure 2.3: Illustration of the contact area between nanoparticles and the surface of stratum 
corneum. Larger particles might have a bigger contact area than smaller particles, considering 
the skin surface is not even.  
 
Figure 2.4 shows the concentration profiles of NR in porcine SC following delivery of the 
active from PS, CAPA and CAB nanoparticles. Uptake of the lipophilic “active” was greatest 
(0.053 µg) from the most hydrophobic polymer (PS) and least (0.029 µg) from the most 
hydrophilic (CAB), with that from CAPA (of intermediate properties) falling in between (0.038 
µg). These differences are influenced, of course, by the different loadings of NR achieved into 
the different nanoparticles (Table 2.1): the “payloads” for PS, CAPA and CAB were 77%, 49% 
and 24%, respectively. If the SC uptake levels are normalized by these different fractional 
loadings (i.e., average amounts of the dye taken up into the SC are divided by the fraction of 
the active eventually associated with the particles), the resulting ratios are 0.69 for PS, 0.78 for 
CAPA and 1.20 for CAB indicating, as would be expected, that NR release from the least 
hydrophobic nanoparticle (into the lipophilic SC) is favored relative to that from the more 
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hydrophobic polymers. 
 
 
Figure 2.4: SC concentration profiles of NR following a 6-hour application of PS, CAPA and 
CAB nanoparticles (n = 5; mean ± SD). 
 
2.3.4 Visualization of NR disposition in the SC by confocal microscopy 
 
To visualize fluorescently-labeled biological samples, laser scanning confocal microscopy 
(LSCM) is a very valuable tool. Its optical sectioning function provides in-depth information 
of thick specimens without perturbation or destruction of the sample [18]. Confocal images 
from the surface of skin treated with nano/mesoparticles revealed the disposition of the 
associated NR post-application. Figure 2.5, for example, shows intense red fluorescence 
around a clearly imaged hair follicle following application of the CAPA 90 nm diameter 
nanoparticles. The affinity of polymeric particles for such appendageal structures has been 
reported previously [17]. Figure 2.6 illustrates NR distribution at the surface of the stratum 
corneum and nicely outlines the polygonal shapes of the corneocytes [19, 20]. Not surprisingly, 
therefore, the NR released from (in this case, CAB) nanoparticles enters the SC via the 
intercellular lipid domains. 
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Figure 2.5: Confocal image (×10) of the skin surface following a 6-hour application of CAPA 
nanoparticles (90 nm diameter) containing NR. Clear localization around a hair follicle is 
observed.  
 
 
 
Figure 2.6: Confocal image (×63) of the skin surface following a 6-hour application of CAB 
nanoparticles containing NR. The release of the fluorophore into the intercellular lipid domains 
clearly outlines the polygonal shapes of the SC corneocytes. 
 
Figure 2.7 illustrates the use of LSCM to optically section through the skin to produce a 
z-stack series of images as a function of depth into the SC and upper epidermis. In this 
example, NR released from CAB nanoparticles is seen to penetrate via the intercellular 
pathway but that it is effectively constrained to the SC, with little evidence of deeper transport 
during the 6-hour application period. Figure 2.8 demonstrates how the z-stack images can be 
CHAPTER 2 
- 67 - 
“reconstructed” to provide a cross-sectional image of the skin by sectioning through a specified 
plane. The NR released from the CAPA 90 nm diameter nanoparticles shown is limited in its 
disposition to the upper layer (primarily the SC) of the skin. Only in the vicinity of a hair 
follicle is there evidence for deeper penetration of the fluorescence.   
 
 
 
Figure 2.7: Optical sectioning images (×63) of skin after a 6-hour application of CAB 
nanoparticles containing NR. The sample area was imaged as the focus plane of the LSCM 
was lowered in steps of 1 µm. 
 
 
 
Figure 2.8: Reconstructed, optical cross-sectional image (×10) of skin after a 6-hour 
application of CAPA (90 nm diameter) nanoparticles containing NR. Penetration of the 
fluorophore is mostly constrained to the SC to a depth of ~10 µm but is occasionally visualized 
further into the tissue around hair follicles as highlighted by the white circle above.  
 
Additionally, skin samples may be mechanically sectioned in the normal way and then 
examined by LSCM at a plane beyond the cut surface (thereby avoiding artifacts associated 
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with the sectioning procedure). This provides an alternative approach to obtain information 
about penetration into the deeper skin layers and has the advantage that it overcomes the 
progressive loss of resolution and signal of confocal microscopy with depth within the tissue, 
due to scattering and absorption of both the laser excitation and fluorescence emission light [21, 
22]. An example of this approach is illustrated in Figure 2.9, which captures a hair follicle 
leaving the skin and demonstrates once more that NR uptake is limited to the SC.  
 
 
 
Figure 2.9: CLSM image of a mechanical cross-section of skin following a 6-hour application 
of CAB nanoparticles containing NR. The fluorophore was visualized in the SC and around a 
hair follicle but did not penetrate into deeper regions of skin. 
 
2.4 Conclusions  
 
The size and the hydrophobicity of nano/mesoparticles clearly influence the local 
disposition of an associated, lipophilic “active” species when applied to the skin. Larger 
particles, with a relatively smaller total surface area encourage the “active” to enter the 
lipophilic stratum corneum more efficiently. Nanoparticles made with more hydrophobic 
polymers are able to bring a greater “payload” of the lipophilic active to the skin surface and 
the absolute uptake into the SC is higher than that from less hydrophobic carriers. However, 
when delivery is more appropriately viewed as the fraction of the payload transferred from 
particle to skin, the expected, improved release from the least hydrophobic polymer (i.e., that 
least sympathetic to the lipophilic “active”) is observed. 
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Confocal microscopy reveals that the released “active” is constrained to the SC and that it 
diffuses into the barrier via the intercellular lipids. Affinity of the formulations for appendageal 
structures, such as hair follicles, is clear, but the present study is unable to distinguish whether 
the red fluorescence seen is free “active”, or “active” still associated with the nanoparticles.  
Resolution of this key question forms the basis of future work. 
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Abstract 
Oil-in-water microcapsules with varying shell thicknesses were fabricated via a coacervation 
technique, whereby evaporation of volatile solvents induced the shell-forming polymer to 
precipitate, phase separate and migrate to the oil/water interface to form microcapsules. These 
microcapsules encapsulated a lipophilic dye within their cores and were applied topically onto 
porcine skin for 6 hours. Results indicated that the dye preferentially accumulated within the skin 
furrows and hair follicles, though the dye did not penetrate beyond the stratum corneum. A model 
estimates the diffusion coefficients of dye through the microcapsule shell and within the skin to 
be approximately 10-18 and 10-16 m2s-1, respectively.  
 
Keywords: Nanocapsules, shell thickness, skin, stratum corneum, Nile Red 
 
3.1 Introduction 
 
In the past 35 years, microcapsules have found broad applications in many drug and vitamin 
products [1, 2], cosmetics, personal care items [3, 4] and foods and beverages [5]. Release 
mechanisms of the encapsulated ingredients include rupture by stress/pressure, shell dissolution 
                                                        
*1 Accepted by European Journal of Pharmaceutics and Biopharmaceutics in November 2008. To whom 
correspondence should be addressed (afr10@cam.ac.uk). 
CHAPTER 3 
- 74 - 
[6], shell permeation [7] and responsive shell swelling [8-11]. This variety provides a range of 
release profiles: for example, shell breakage and/or dissolution offers immediate release, while 
permeable and/or swellable shells are more useful for gradual, targeted release.  
 
Despite their widespread use, however, safety concerns remain about the fate of 
microstructures in the human organism [12], an issue which has achieved even greater 
prominence with the advent of ‘nanotechnology’ in recent years. The motivation for this work 
lies in the investigation of percutaneous transport of an encapsulated ingredient into the skin from 
permeable microcapsules with varying shell thicknesses. This, coupled to a simple model for the 
diffusion profiles, crucially allows the understanding of individual control parameters for the 
‘active’ ingredient movement within each environment (polymeric shell and skin). Hence, in this 
paper, polystyrene microcapsules (700 – 900 nm) had been used to encapsulate a model, ‘active’ 
ingredient (Nile Red dye) and then applied topically on porcine skin. Subsequently, the release 
and penetration of the ‘active’ was investigated and the results modeled.  
 
Microcapsules were prepared using a previously reported coacervation method [13-15], 
whereby the shell-forming polymer and oil core are initially premixed in a volatile solvent, in 
which the polymer is soluble. The oil phase is then emulsified in an aqueous solution and the 
emulsification intensity determines the size of capsules formed. As the volatile solvent evaporates, 
the polymer precipitates from the oil phase. Given the right wetting conditions, the polymer will 
migrate to the water/oil interface and envelope the oil droplet to form a complete spherical shell. 
The final morphology of the particles is governed by the relative interfacial energies between the 
various phases [13]. 
 
Porcine skin has been used as a substitute for human skin, which it closely resembles in terms 
of epidermal thickness, lipid composition, permeability to diverse compounds and overall barrier 
function [16]. The latter is furnished by the stratum corneum, the thin (~10 µm) outermost layer 
of the skin. It has been described as a “brick and mortar” structure [17], in which corneocytes are 
embedded in an intercellular lipid matrix composed of ceramides, free fatty acids and cholesterol.  
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3.2 Theory 
3.2.1 Dye diffusion model 
 
The polystyrene shells encapsulated Nile Red dye and hexadecane cores. As the formulation 
of microcapsules came into contact with the porcine skin, passive diffusion of dye from the oil 
core into the skin takes place over the duration of the application time. This dye diffusion process 
is described by Fick’s second law of diffusion. 
2
2
x
cD
t
c
∂
∂=∂
∂
                             (1) 
Figure 3.1 presents the system schematically, with the microcapsule encapsulating the active 
(in this work, the dye, Nile Red) at a concentration CNR. The microcapsules have a shell thickness 
of Ls and diffusion of dye through the shell is characterized by a diffusion coefficient, Ds. The 
microcapsules are in contact with the stratum corneum, of thickness L. The Nile Red diffusion 
coefficient through the skin is D, and its concentration within the stratum corneum is represented 
by c and is a function of application time (t) and distance (x) into the membrane.   
 
 
Figure 3.1: Schematic diagram illustrating the basis of the mathematical model developed (not to 
scale). 
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The applicable boundary conditions are: 
(i) At x = 0, 0=∂
∂
x
c ,   
which represents no flux of material at the inner surface of the skin. 
(ii) At x = L, ( )
x
cD
L
cCD
s
NRs
∂
∂=− ,  
which represents a balance between the amount of dye passing through the shell and that passing 
through the stratum corneum.   
 
For ease of calculation, the concentration gradient, (CNR – c), is normalized by the Nile Red 
concentration in the oil core. The thickness of capsule shell is also normalized, in this case, by the 
thickness of the stratum corneum yielding the dimensionless parameters:  
               1ˆ −=
NRC
cc     and    
L
xx =ˆ                              (2) 
and the simplified form of Equation (1): 
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with revised boundary conditions: 
(i) At 0ˆ =x , 0ˆ
ˆ =∂
∂
x
c
. 
(ii) At 1ˆ =x , c
L
LD
x
cD
s
s ˆ
ˆ
ˆ −=∂
∂
. 
 
Solution is obtained by separation of variables, resulting in an Eigenfunction series with the 
Eigenfunction, λ, given by the solution to: 
CHAPTER 3 
- 77 - 
             
s
s
DL
LD=λλ tan                                      (4) 
and the solution for concentration as follows: 
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with the values of An obtained from: 
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In summary, the diffusion of dye through the microcapsule shell into the stratum corneum is 
characterized by Equation (5), with λn provided in Equation (4) and the corresponding An 
calculated from Equation (6), where n = 1, 2, 3… 
 
3.2.2 Solution when CNR >> c 
 
When the ‘active’ concentration within the oil core, CNR, is much greater than that within the 
stratum corneum, c, (i.e., CNR >> c), then the concentration difference (CNR – c) dominates the 
passive diffusion process, which is no longer governed by the thickness of the shell.  
 
Using Figure 3.1 with the illustrated symbols and notations, together with Equation (1) and the 
corresponding boundary conditions given before, and defining: 
               sLcc ×=(           and     L
xx =ˆ              (7) 
then: 
                                 2
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and: 
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However, since CNR >> c or c/CNR << 1, then the second boundary condition becomes: 
                         
D
LCD
x
c NRs=∂
∂
ˆ
(
                     (9) 
which is independent of the capsule shell thickness, Ls. 
 
Therefore, the solutions to Equation (8) will be independent of shell thickness, Ls, and the data 
obtained from different microcapsules should then collapse on to a single profile, providing a 
simple proof that the dye diffusion through the stratum corneum follows simple Fickian 
diffusion.  
 
3.3 Materials and methods 
 
3.3.1 Materials 
 
Polystyrene (melt index 14, MW ~ 225,000 g/mol, Aldrich, Dorset UK) was used to form the 
microcapsule shells. Dichloromethane (99%, Acros Organics, Loughborough UK) was the 
volatile polymer solvent. n-Hexadecane (99%, Fisher Scientific, Loughborough UK) was 
employed without purification as the non-volatile, non-solvent oil core. Acetone (>99%, Aldrich) 
was added to aid the emulsification process. Poly(vinyl alcohol) (96% hydrolysed - average MW 
85,000 – 124,000 g/mol, Aldrich) was the external aqueous phase after dilution to 2% w/v 
solution with MilliQ water (18.2 MΩ•cm). Nile Red (Aldrich), a fluorescent dye, was the 
encapsulated, lipophilic ‘active’. Acetonitrile (HPLC grade, Aldrich) was the solvent used in the 
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high performance liquid chromatography (HPLC) assay of Nile Red (see below). 
 
Anhydrous sodium phosphate dibasic (Acros Organics), potassium dihydrogen phosphate 
monobasic (Acros Organics) and sodium chloride (Acros Organics) were used to make phosphate 
buffered solutions. Phosphoric acid (85% in solution, Acros Organics) was added for pH 
adjustment. Porcine skin was obtained from four 1-year old pigs (two female, two male) from a 
local slaughterhouse. Tissue was dermatomed to a nominal depth of 750 µm, then cut into 4 cm × 
6 cm pieces. The skin samples were washed under cold running water, dried and sealed in plastic 
bags at -20°C until used.  
 
3.3.2 Methods 
 
3.3.2.1 Fabrication of polystyrene microcapsules with encapsulated dye  
 
Polystyrene microcapsules were made using a coacervation technique; the precipitated 
polymer induced by internal phase separation enveloped the oil core to form a complete shell 
[13-15, 18]. Nile Red (1.6 mg) was first pre-dissolved in hexadecane (24 g) and acetone (6.2 g). 
The presence of acetone facilitated dissolution without causing phase separation from 
hexadecane. This mixture was then separated into four identical batches.  
 
Next, polystyrene (3.2–16 g) was dissolved in dichloromethane (110.2 g) and a batch of the 
Nile Red containing oil phase was added. Additional acetone (4.65 g) was introduced to aid the 
subsequent emulsification process. Meanwhile, 2% w/v poly(vinyl alcohol) solution (125 mL) 
was poured into a 400 ml beaker and thermostatted at 20°C.  
 
With the aqueous phase being stirred at approximately 9,200 rpm, the oil phase was gradually 
added over ~1 minute to form an oil-in-water emulsion. Stirring was continued for 1 hour. 
Subsequently, the emulsion was heated, with gentle stirring, from 20°C to 65°C over 20 minutes 
and was then maintained at this elevated temperature for a further 40 minutes. The temperature 
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was then reduced to 40°C and held for 4 hours. Finally, the emulsion was left overnight in a fume 
cupboard at atmospheric conditions, again with gentle stirring. This ensured that all the 
dichloromethane and acetone had evaporated and allowed for complete polystyrene shell 
formation. The formed microcapsules were then placed in sealed containers and kept in the dark 
until use. 
 
3.3.2.2 Characterization of polystyrene microcapsules 
 
The microcapsules were characterized by scanning electron microscopy (SEM). A 
JEOL-6340F Field Emission Gun Scanning Electron Microscope was used to image the 
morphology of the microcapsules at an accelerating voltage of 5 kV. A drop of the microcapsule 
suspension was air-dried on a stainless steel SEM stub overnight. The sample was then 
platinum-coated using an Emitech K575 sputter coater. This was carried out under argon at 
1×10-3 millibar and 40 mA for 1 minute.  
 
The microcapsule diameters were measured by dynamic light scattering (Brookhaven ZetaPlus, 
Brookhaven Instruments Corporation, Holtsville NY, USA). A drop of the microcapsule 
dispersion (approximately 0.1 ml) was placed in a disposable plastic cell and diluted to 3 ml. The 
effective diameters deduced were accurate to ±1%, with an average of 10 measurements taken. 
 
3.3.2.3 Dye diffusion study  
 
Before the experiment, the skin was fully defrosted and any visible hairs were trimmed as 
close as possible to the surface. Each piece of skin was cut in half, one part being used for the 
Nile Red diffusion experiment, the other reserved for the measurement of stratum corneum 
thickness (see below).  
 
The former piece of skin was clamped between the donor and receptor compartments of a 
vertical Franz diffusion cell. The receptor compartment was filled with phosphate buffer solution. 
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The donor solution was 3 ml of a polystyrene microcapsule formulation and was covered with 
Parafilm to prevent evaporation. Replicate cells (n = 3) were positioned on a Skin Permeation 
System (Model LG-1083, Laboratory Glass Apparatus Inc, Berkeley CA, USA), which allowed 
magnetic stirring of the receptor phases and provided a means to thermostat the cells at 37ºC. 
Diffusion was allowed to proceed for 6 hours, at which point the experiment was terminated, the 
skin removed and gently washed three times with phosphate buffer solution, and patted dry with 
paper towel.   
 
Subsequently, the depth of Nile Red penetration into the stratum corneum of porcine skin was 
assessed using a validated tape-stripping procedure [19]. Briefly, twenty 2.7 cm × 2.7 cm square 
tapes were first cut from transparent Scotch adhesive book tape 845. Each tape was weighed pre- 
and post-skin stripping. A circular template with a 2 cm diameter hole was prepared and secured 
onto the treated skin. The stratum corneum was then stripped twenty times with the pre-weighed 
tapes. After, each tape was rolled and placed in 1 mL acetonitrile in a 2 mL glass vial. The vials 
were capped and shaken overnight. The next day, the samples were filtered (Whatman PTFE 
filters, 0.45 µm, Florham Park, NJ USA) into HPLC vials. The experimental solutions, together 
with known concentration standards of Nile Red, were assayed by HPLC. 
 
3.3.2.4 High-performance liquid chromatography assay  
 
Nile Red was quantified by HPLC with fluorescence detection. The chromatographic system 
(Dionex, Sunnyvale, CA USA) was equipped with a RF 2000 fluorescence detector and a 
reversed-phase column (25 cm × 4.6 mm internal diameter, KYA Tech, Tokyo Japan). The system 
was set at 559 nm and 630 nm for excitation and emission wavelengths, respectively. The mobile 
phase was acetonitrile-water (80:20) with a flow rate of 1 ml/min. Each injection utilized 200 µL 
of solution maintained at 25°C. The Nile Red retention time was 12.6 minutes. The limits of 
detection and quantitation were 0.3 ng/ml and 1.1 ng/ml, respectively. 
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3.3.2.5 Stratum corneum thickness determination  
 
The second half of each skin section was used for measurement of stratum corneum thickness 
using a previously published method [20]. Stratum corneum removal using pre-weighed 
tape-strips was again employed, having delimited a 2 cm diameter area of skin with a circular 
template. Prior to the first strip and following the removal of each layer, the passive 
transepidermal water loss (TEWL) across the skin was measured with an Aquaflux device (Biox 
Systems Ltd., London UK) specifically designed for this purpose. Stripping was continued until 
TEWL reached 80 g m-2 h-1 [20]. Then, the tapes were reweighed to determine the amount (and, 
hence, the thickness) of stratum corneum removed on each tape-strip. The reciprocal of TEWL 
was plotted against the cumulative thickness of stratum corneum removed and the resulting linear 
regression was extrapolated to TEWL-1 = 0 to yield the total stratum corneum thickness as the 
intercept on the x-axis. 
 
3.3.2.6 Laser scanning confocal microscopy 
 
After 6 hours exposure to the Nile Red microcapsule formulation, the skin was cleaned and 
then examined by laser scanning confocal microscopy (LSM 510 Meta, Carl Zeiss, Jena 
Germany). A HeNe laser was used to excite Nile Red at 543 nm. The skin was then inspected 
under 10×, 20× and 63× objectives. Confocal images were recorded and edited with LSM Image 
Browser software (Carl Zeiss, Release 4.0).  
3.4 Results and discussion 
 
3.4.1 Polystyrene microcapsules 
 
Figure 3.2 is a SEM image of polystyrene microcapsules encapsulating Nile Red. The 
capsules are spherical and range in size from 500 nm to 1 µm. This was confirmed quantitatively 
by dynamic light scattering, which gave an average effective diameter of 750 nm. Some 
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microcapsules appeared to have a hole within their shells, and these structures have been termed 
“colloidal buckets”. It is believed that the formation of these structures (which will be discussed 
in a separate article) is triggered by the presence of excess dye. As most of the particles formed 
did not display this feature, the analysis of the results assumed a continuous shell. NR is 
distributed in both the core and the shell.  
 
 
 
Figure 3.2: Scanning electron microscopy image of polystyrene microparticles. 
 
Five sets of polystyrene microcapsules were fabricated with varying shell thickness. This was 
achieved either by varying the amount of polystyrene or by decreasing the hexadecane content. 
The crucial element is the volume ratio of the shell-forming polymer to the non-volatile oil. This 
ratio governs the total surface area that the polymer must cover to form a complete shell and, in 
turn, for a given capsule diameter, determines the thickness of the shell that the precipitating 
polymer can produce.  
 
To calculate the shell thickness, it is assumed that volume is conserved [13]. For a capsule of 
radius, r, with shell thickness, Ls, the ratio of volume occupied by the shell, Vs, to the total 
volume of the capsule, Vt, is: 
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This ratio equals the volume fraction of polystyrene (φp) within the non-volatile non-solvent 
oil. In this study, the oil phase is hexadecane. Hence, equation (10) can be rearranged as: 
                     ( ) 3111 psrL φ−−=                         (11) 
Hence, as φp is known and the radius of the microcapsules is determined by dynamic light 
scattering, the shell thickness, Ls, can be calculated. The results for the different microcapsules 
are in Table 3.1. For the first, second and fourth series, the average capsule radius was 431±12 
nm and, with a 3-fold increase in polymer content, Ls approximately doubled; for the third and 
fifth sets, reducing the amount of hexadecane by a factor of 2 resulted in a 1.5-fold increase in Ls. 
In summary, therefore, it proved possible to obtain a range of microcapsules with varying shell 
thickness to examine in subsequent experiments. 
 
Table 3.1: Properties of the various polystyrene microcapsules investigated. 
Polystyrene 
content 
Hexadecane 
content 
Polymer 
fraction, φp 
1 Capsule 
radius, r 
Shell thickness, 
Ls Set 
(cm3) (cm3) (%) (nm) (nm) 
1 3.1 8.7 26 425 40 
2 5.9 8.7 40 445 70 
3 11.9 10.3 54 360 82 
4 9.0 8.7 51 425 89 
5 11.8 5.0 70 360 120 
 
 1 Measured by dynamic light scattering. 
 
3.4.2 Confocal microscope imaging of skin 
 
Figure 3.3 shows that Nile Red had accumulated in the furrows, of the skin (Figure 3.3a) and 
in and around the hair follicle openings (Figure 3.3b). It is perhaps not surprising that this 
lipophilic fluorophore showed a predilection for these lipid-rich sites on or near the skin surface, 
and the data are consistent with earlier observations [21]. However, these skin appendages only 
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cover 0.1% of the total skin surface; hence the contribution of this to percutaneous transport is 
considered minimal [22]. It is generally the intercellular lipid matrix that is the main barrier to 
percutaneous transport.  
 
 
 
Figure 3.3: Laser scanning confocal microscopy image showing Nile Red disposition (a) in skin 
furrows and (b) in and around a hair follicle.  
 
3.4.3 Skin penetration of Nile Red 
 
The thickness of the stratum corneum of ten pieces of porcine skin was determined via 
measurements of TEWL. Examples of the data obtained are shown in Figure 3.4. The x-axis 
intercept gives the total thickness of the stratum corneum. Therefore, the average (±SD) stratum 
corneum thickness is 10 ± 2 µm. With this information, it was possible to display all Nile Red 
concentration profiles across the barrier as a function of normalized position (from 0 at the skin 
surface to 1 at the interface with the underlying viable tissue). The Nile Red concentrations were 
obtained by dividing the Nile Red amount, as detected by HPLC, by the volume of stratum 
corneum, assuming a density of 1 g cm-3 [23].    
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Figure 3.4: Example TEWL results enabling stratum corneum thickness determination. 
 
The Nile Red concentration profiles observed as a function of microcapsule shell thickness are 
illustrated in Figure 3.5. The diffusion of dye into the deeper regions of the stratum corneum 
indicates that it has been released from the microparticles, the size of which are clearly too large 
to cross an intact cutaneous barrier [24]. Apparent from the data, however, is that a gradual 
increase in the microcapsule shell thickness resulted in a decrease in the amount of Nile Red 
taken up into the stratum corneum. This has been confirmed quantitatively by integration of the 
area under the concentration profiles to give the calculated total amount of Nile Red uptake as a 
function of microcapsule thickness (Table 3.2). These results suggest a means whereby the 
uptake of an ‘active’ ingredient into the skin may be manipulated by judicious design of the 
formulation employed. As NR is in both the core and the shell of the microcapsules, it may 
exhibit a “burst release” from the carriers at the initial stage of application, a sign of NR released 
from the shell, and then the rate of release reduces until it becomes constant, indicating NR is 
released from the core [14, 15].  
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Figure 3.5: Nile Red concentration profiles across the stratum corneum (mean ± SD; n = 3) as a 
function of the relative depth of penetration into the barrier following a 6-hour application of five 
formulations of microcapsules of different shell thickness (ST).  
 
Table 3.2: Total amount of Nile Red taken into the stratum corneum, determined by integration 
of the area under the curves in Figure 3.5. 
Capsule ST (nm) Total Nile Red taken into the SC (µg/ml) 
40 3.3 ± 0.2 
70 2.6 ± 0.2 
82 2.2 ± 0.2 
89 1.8 ± 0.1 
120 1.4 ± 0.1 
 
3.4.4 Model fitting of of NR concentration profiles across SC 
 
The Nile Red concentration profiles across the stratum corneum were fitted to the theoretical 
model, using ten terms in the Eigenfunction expansion to ensure convergence. The best fits to the 
data (Figure 3.6a) were obtained with D = 5 x 10-16 m2 s-1 and Ds = 1.5 x 10-18 m2 s-1. To the 
authors’ best knowledge, no coefficient data had been quoted for diffusion of Nile Red dye in pig 
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skin or polystyrene shell. Comparing with similar release studies, the proposed coefficients were 
comparable to literature; 10-15–10-16 m2 s-1 for D [25, 26] and 10-16–10-21 m2 s-1 for Ds [7, 27]. The 
diffusion of an active is generally governed by its size, solubility in the diffusion medium and 
nature of the diffusion medium. The sensitivity of the fitting to the values of the proposed 
diffusivities is illustrated in Figures 3.6b and 3.6c. Predictably, as D is increased from 10-17 to 
10-14 m2 s-1, the ‘active’ distributes further into the barrier and the profile becomes progressively 
less steep (Figure 3.6b). On the other hand, as Ds is increased from 10-20 to 10-17 m2 s-1, the total 
amount of ‘active’ in the stratum corneum increases progressively as its release from the 
microcapsules becomes faster (Figure 3.6c). Overall, therefore, diffusivity in the shell determines 
the absolute quantity of ‘active’ transferred into the stratum corneum, while its diffusivity in this 
membrane controls the depth of penetration into the barrier.  
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Figure 3.6: (a) Comparison of normalized Nile Red concentration (c/CNR) profiles (mean ± SD; 
n=3) across the stratum corneum with the theoretical predictions (continuous lines) of the method 
for “active” delivery from microcapsules of different shell thickness (ST), with subsequent model 
predictions of the normalized Nile Red concentration (c/CNR) profile for various values of 
diffusion coefficient of the “active” (b) across the stratum corneum, D, and (c) through the 
polymeric microcapsule shell, Ds.  
1 The data points shown are for Nile Red delivered from a formulation containing microcapsules of shell 
thickness 40 nm and having D = 5 x 10-16 m2 s-1. 
2 The data points shown are for Nile Red delivered from a formulation containing microcapsules of shell 
thickness 40 nm with Ds = 1.5 x 10-18 m2 s-1. 
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The Nile Red profiles in Figure 3.6a indicate that the concentration of ‘active’ in the oil core is 
much greater than that achieved in the stratum corneum. The approximate solution to the 
diffusion equation when CNR >> c can be applied, and the theoretical prediction that the 
behaviour of (c x Ls), as a function of penetration depth (x) into the stratum corneum, is 
independent of microcapsule shell thickness may be examined. This test is undertaken in Figure 
3.7, and a collapse of the data on to a single profile is observed. Hence, this confirms that the dye 
diffusion process into the porcine skin is governed by Fickian diffusion.  
 
 
Figure 3.7: Predicted collapse of concentration profile data in Figure 3.5 to an essentially 
common profile when CNR >> c (the case for these experiments) (Data: mean ± SD; n = 3).  
 
3.5 Conclusions 
 
A range of polystyrene microcapsules, encapsulating Nile Red in a hexadecane core, were 
prepared and examined for their ability to deliver a model ‘active’ substance to the outer layers of 
mammalian skin. Increasing shell thickness reduced the rate and extent of ‘active’ transfer into 
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the outermost, and least permeable, layer of skin, the stratum corneum. The concentration 
profiles were successfully simulated with a diffusion model, which took into account the active’s 
diffusivities in the stratum corneum and in the polymeric shell. The results suggested that the 
approach might be useful for the design and optimisation of consumer-health formulations for 
diverse applications. 
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Abstract 
Purpose: To determine the disposition of nanoparticles (NP) and an associated, lipophilic, 
model “active” on and within the skin following topical application. Methods: Fluorescein 
methacrylate and Nile Red-containing polystyrene and polymethylmethacrylate NP were 
prepared to differentiate the fate of the polymeric vehicle on and within the skin from that of the 
active ingredient. Fluorescein methacrylate was covalently introduced into the polymer, and NR 
was dispersed in the NP, which were characterized by dynamic light scattering, transmission 
electron microscopy and NMR. In-vitro skin permeation experiments were performed using 
dermatomed porcine skin. Post-treatment with NP formulations, the skin surface was either 
cleaned carefully with physiological buffer, or was simply dried with tissue, and then 
immediately visualized by confocal microscopy. Results: The mean NP diameters were less than 
100 nm. Confocal images showed that NP were located post-treatment in skin “furrows” and 
around hair follicles. Surface cleaning with buffer removed the former but not all of the latter. At 
the skin surface, Nile Red remained in part associated with NP, but release of the “active” clearly 
occurred to some extent followed by its penetration into deeper layers of the stratum corneum 
(SC). Conclusions: The polymeric NP studied did not penetrate beyond the superficial SC but 
showed some affinity for hair follicles, and were able to release an associated “active” into the 
skin.  
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Keywords: Nanoparticles, skin, penetration, polystyrene, poly-(methyl methacrylate), confocal 
microscopy, stratum corneum.  
 
4.1 Introduction 
 
Recently, polymeric nanoparticles (NP) have been proposed as carriers for drugs and other 
active agents administered by topical administration. Examples include anti-inflammatory drugs 
[1, 2], anti-infective drugs [3], vitamins and sunscreens [4-6]. It has been claimed that 
drug-loaded NP achieve sustained release and consequently improve the therapeutic effect of 
dermatological formulations [2, 3]. More importantly, NP can increase the stability of sensitive 
actives by protecting the molecules in a polymeric shell. Based on this, NP have been 
incorporated into several commercially available cosmetic products to encapsulate various 
actives (e.g., vitamin A, Rose extract and wheat germ oil).  
 
The development of topical formulations containing nano-sized materials has also been 
challenged by mechanistic and toxicity issues. Compared with larger particles, it has been 
suggested that nanostructures are more likely to penetrate the stratum corneum and gain access to 
the living cells within the epidermis and dermis. Should this be possible, then systemic exposure 
might occur (i.e., the nanoparticles being taken up into the blood and distributed to various 
tissues and organs), presenting thereby a potential toxicity risk for human health [7-10]. 
Therefore, understanding the topical disposition of both vehicle and active is essential for the use 
of nano-engineered topical formulations. Whether (and when) the active is released from the 
vehicle, and the fate of the vehicle itself, are very important questions concerning the safety of 
nanotechnology. To begin to address these issues, two series of polymeric NP have been prepared 
in which the polymer was covalently-labelled with fluorescein methacrylate (FMA, Figure 4.1a). 
A second fluorescent compound, Nile Red (NR, Figure 4.1b) was incorporated into the particles 
to simulate a hydrophobic active. Laser scanning confocal microscopy (LSCM) was used to track 
both fluorophores after topical application to porcine skin. Porcine skin is a good substitute for 
human skin having epidermal thickness, lipid composition, permeability, transepidermal water 
loss and low frequency impedance values which are very similar [11, 12].  
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Figure 4.1: Chemical structures of fluorescein methacrylate (FMA) and Nile Red (NR). 
 
4.2 Materials  
 
4.2.1 Tissue 
 
Full thickness porcine skin was obtained from a local slaughterhouse. The skin was cleaned 
carefully under cold running water. The subcutaneous fat was removed with a scalpel. The 
remaining tissue was dermatomed to a thickness of ~750 µm. Finally, the dermatomed skin was 
stored frozen at -20°C for up to a maximum of one month before use. 
 
4.2.2 Chemicals 
 
Fluorescein O-Methacrylate (97% pure), Nile Red (analytical grade) and polystyrene (PS, 
MW: 44,000) were purchased from Sigma-Aldrich (St. Louis, MO, USA).  
 
Styrene (99% GC), methyl methacrylate (99% GC) and potassium persulfate (KPS) were 
purchased from Sigma-Aldrich (Gillingham, Dorset, England). Other chemicals used were 
polymethylmethacrylate (PMMA, MW = 50,000 Fluka Analytical, Steinhelm, Germany), sodium 
dodecylsulphate (SDS, 99+% GC, Sigma-Aldrich, Japan), ruthenium tetroxide (Taab 
Laboratories, Aldermaston, England), phosphotungstic acid (Agar Scientific Ltd., Stansted, UK), 
and chloroform-d1 (ISOTEC TM, Miamisburg, OH, USA).  
4.3 Methods 
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4.3.1 Nanoparticle (NP) preparation 
 
Before use, inhibitors were removed from the vinyl monomers by passage through an alumina 
column. The NP were prepared in an inert nitrogen atmosphere by free radical polymerization 
(see Figure 4.2). 200 cm3 distilled water was placed in a round bottom flask, with 1 g of SDS 
added as an emulsifier. The aqueous surfactant solution was deoxygenated with N2 to remove 
oxygen. 13 g of deoxygenated styrene were added into the aqueous phase. The mixture was 
vigorously stirred to form an emulsion and heated to 75°C. To start the polymerization, 0.1 g 
KPS dissolved in a small amount of water was added. The reaction was allowed to proceed under 
nitrogen for 3 hours. To prepare fluorescently labeled NP, 0.13 g of FMA and/or 0.13 g NR were 
mixed with the monomer before addition to the reaction. The same procedure was used for the 
preparation of PMMA NP.   
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Figure 4.2: Polymerization of styrene (Reaction A) and methyl methacrylate (MMA) (Reaction 
B) with fluorescein methacrylate (FMA) using potassium persulfate (KPS) as an initiator at 75°C. 
 
CHAPTER 4 
- 100 - 
4.3.2 NP characterization 
 
The mean size and polydispersity of the NP were measured with dynamic light scattering 
(DLS BI90Plus, Brookhaven Instruments Corporation, NY, USA). The morphology of the 
nanoparticles was observed on a JEOL JEM-2000 TEM at an accelerating voltage of 120kV. 
Each sample was prepared by casting a drop of NP dispersion onto a 300-mesh copper grid 
covered with carbon film. TEM images of PS NP were obtained as positively stained preparations 
by placing samples in ruthenium tetroxide vapour for 1 hr. TEM images of PMMA NP were 
obtained as negatively stained preparations by placing samples in phosphotungstic acid for 1 hour. 
1H NMR spectra were recorded in deuterated chloroform (CDCl3) on a Bruker Avance™ III 
spectrometer (Billerica, MA, USA) operating at 400 MHz. Prior to analysis, the NP were washed 
with water and acetone to remove SDS and unreacted compounds, and freeze-dried (Heto 
PowerDry PL3000, Thermo Electron corporation, Waltham, MA, USA). 
 
4.3.3 In vitro skin permeation 
 
Before the experiment, the hairs were trimmed as close as possible to the skin surface. Skin 
permeation experiments were performed in vertical Franz diffusion cells thermostated at 37°C. The 
excised tissue was clamped between the donor and receptor compartments exposing a diffusion area 
of 3.8 cm2. The receptor compartment was filled with physiological buffer (pH = 7.4); the donor 
compartment held 1 cm3 of the NP formulation and was covered with Parafilm. After 6 hrs of 
exposure, the cell was dismantled, and the skin surface was either cleaned carefully with 
physiological buffer or was simply patted dry with tissue and then immediately visualized by 
confocal microscopy.  
 
4.3.4 Laser scanning confocal microscopy (LSCM) 
 
The skin was examined using a LSM 510 Invert Laser Scanning Microscope (Carl Zeiss, Jena, 
Germany). The system was equipped with an argon laser (excitation line at 488 nm) and a HeNe 
laser (excitation line at 543 nm). A Plan-Neofluar 10×/0.3 objective, an EC Plan-Neofluar 40×/1.30 
oil DIC M27 objective and a Plan-Apochromat 63×/1.40 oil DIC M27 objective were used. Confocal 
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images were obtained in the plane parallel to the sample surface (xy-mode), or in the plane 
perpendicular (optical sectioning z-stack mode).  
 
4.4 Results 
 
4.4.1 NP characterization  
 
Table 4.1 summarizes the properties of the NP formulations used in the in vitro permeation 
experiments.  
 
Table 4.1: Properties of the PS and PMMA nanoparticulate (NP) formulations examined a 
NP Formulation Dyes included Mean size (nm) Polydispersity 
PS None 28.8 0.135 
PS-FMA FMA 28.0 0.141 
PS-FMA-NR FMA and NR 30.9 0.118 
PMMA None 79.0 0.171 
PMMA-FMA FMA 99.9 0.163 
PMMA-FMA-NR FMA and NR 68.5 0.133 
 
a. PS = polystyrene; PMMA = polymethylmethacrylate; FMA = fluorescein methacrylate; NR = Nile Red 
 
The individual NP were spherical and smooth as shown in Figure 4.3. The mean diameter of 
PS NP was less than 50 nm, while the PMMA NP were almost twice as large; these findings were 
confirmed by dynamic light scattering.  
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Figure 4.3: Transmission electron micrograph of PS and PMMA nanoparticles stained with 
ruthenium tetroxide (a, b and c, scale bar = 50 nm) or phosphotungstic acid (d, e, and f, scale bar 
= 200 nm). (a) Polystyrene NP alone, (b) polystyrene with fluorescein methacrylate (FMA) 
polymerized, (c) polystyrene with FMA polymerized and Nile Red (NR) absorbed, (d) 
polymethylmethacrylate (PMMA) NP alone, (e) PMMA with FMA polymerized, and (f) PMMA 
with FMA polymerized and NR absorbed.  
 
Proton NMR spectra of polystyrene, FMA, PMMA and the two copolymers are shown in 
Figure 4.4. Those of the copolymers show signals from either PS or PMMA and FMA even after 
extensive dissolution/reprecipitation, indicating that FMA is covalently bound to the polymer.  
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Figure 4.4: 1H NMR spectra for (a) PS, FMA and PS-FMA copolymer, and (b) PMMA, FMA 
and PMMA-FMA copolymer, together with the structures and chemical shift assignments of (c) 
PS, and (d) PMMA. 
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4.4.2 LSCM images 
 
Nile Red is commonly used to stain intracellular lipids, because it has an intense and stable 
red fluorescent emission under the excitation of HeNe laser at 543 nm. It is also a useful model 
for a topical/transdermal active because of its high lipophilicity (log Po/w > 3) [13] and suitable 
molecular weight (318.4 g.mol-1). FMA is a fluorescent monomer containing a polymerizable 
methyl acrylate functional group which can react with styrene and MMA. Under excitation at 488 
nm, FMA generates a bright green fluorescence, which locates the NP as the dye is covalently 
bound to polymer. The use of NR and FMA allowed the fate of the NP and of the model 
lipophilic active to be monitored independently and simultaneously in the same experiment.  
 
4.4.2.1 Control experiments 
 
For each formulation, two control experiments were performed to validate the methodology 
used. Firstly, PS and PMMA nanoparticle formulations without FMA were separately applied to 
the skin surface. Figures 4.5a and 4.5d show the resulting confocal images, which manifest only 
very weak green fluorescence that is endogenous to the SC. When the fluorescently-labelled NP 
formulations were applied to the skin, distinctly different LSCM images were observed when the 
skin was either cleaned properly, or not cleaned at all. Figures 4.5b and 4.5e from the latter 
samples show that the NP were located in the skin furrows and around the hair follicles. In 
contrast, when the skin was cleaned (Figures 4.5c and 4.5f), there was almost no residual 
fluorescence, suggesting that the NP had remained at the surface and were then easily removed 
by the simple washing procedure.  
 
CHAPTER 4 
- 105 - 
 
 
Figure 4.5: LSCM images of the skin surface following a 6-hour application of PS (panels a, b, c) 
or PMMA nanoparticles (panels d, e, f). In panels a and d, the NP were not fluorescently labelled 
with FMA and only a weak green fluorescence from the skin itself is seen. In panels b and e, the 
NP were fluorescently tagged and the skin surface was not cleaned before imaging; bright green 
fluorescence is apparent in the skin furrows and around the hair follicles. In panels c and f, the 
skin surface was cleaned before the confocal images were obtained; only the residual 
autofluorescence from the skin is observed suggesting that the NP had been effectively removed 
by the cleaning procedure. 
 
4.4.2.2 LSCM images of skin treated with dual-labelled fluorescent NP without 
surface cleaning 
 
For skin samples treated with dual fluorophore-labelled NP formulations, LSCM images were 
acquired using multitracking-mode with excitation wavelengths set at 488nm and 543nm. The 
fluorescence emission from the two dyes was captured separately and overlaid. Figure 4.6 and 
Figure 4.7 illustrate the disposition of the NP and of Nile Red on and within the skin, the surface 
of which was not cleaned at the end of the application period, of the polystyrene and 
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polymethylmethacrylate formulations, respectively. Location of the NP is shown by green 
fluorescence (from FMA covalently attached to the polymer), while the presence of Nile Red is 
highlighted in red. For the polystyrene formulation, NP and NR are seen on the skin surface and 
show clear residence in the skin furrows and around the follicular openings (Figures 4.6a and 
4.6b). Overlay of green and red fluorescence in Figure 4.6c clearly emphasizes the 
co-localization of NP and active.  
 
To examine the fate of the formulation as a function of depth into the skin, the tissue was 
mechanically sectioned post-treatment and then examined by LSCM at a plane beyond the 
mechanical section. The dispositions of NP and NR are shown in Figures 4.6d and 4.6e, 
respectively. Both images highlight a short, trimmed hair shaft on which NP and NR are 
co-localized. Again, NP are at the surface and NR is seen there too. However, separation of NR 
from the nanoparticles is apparent (Figure 4.6f, the overlay) with some permeation of the 
“active” to the deeper skin layers.  
 
The corresponding images for the polymethylmethacrylate NP containing NR are in Figure 4.7. 
Co-localization of the fluorophores in skin furrows (Figures 4.7a and 4.7b) is again observed, 
although the overlay (Figure 4.7c) suggests that Nile Red has already been released to some 
extent at the skin surface. The cross-sectioned images (Figures 4.7d, 4.7e and 4.7f) reveal similar 
behaviour and again highlight an intensely labelled hair stub.   
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Figure 4.6: LSCM images (×10) from skin treated with fluorescently-labelled polystyrene NP 
(31 nm diameter) containing the model active NR. Panels a and b show fluorescence emission 
from the skin surface from the NP (panel a) and NR (panel b), respectively. Panel c shows the 
overlay of panels a and b and the co-localization of NP and “active” at the skin surface. Panels d 
and e illustrate cross-sectional images, respectively highlighting fluorescence from the NP and 
from NR. A distinctly labelled, short, trimmed hair is visible. Panel f is the overlay of panels d 
and e and suggests some permeation of released NR to the deeper skin layers. 
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Figure 4.7: LSCM images (×10) from skin treated with fluorescently labelled 
polymethylmethacrylate NP (69 nm diameter) containing the model active NR. Panels a and b 
show fluorescence emission from the skin surface from the NP (panel a) and NR (panel b), 
respectively. Panel c shows the overlay of panels a and b, the presence of NP in the skin furrows 
and the release of NR from the NP at the skin surface. Panels d and e illustrate cross-sectional 
images, respectively highlighting fluorescence from the NP and from NR. Another short hair stub 
is visibly labelled. Panel f is the overlay of panels d and e and again reveals some degree of 
separation between NP and NR. 
 
4.4.2.3 LCSM images of skin treated with dual-labelled fluorescent NP after 
surface cleaning 
 
When the skin surface was properly cleaned by washing with buffer at the end of the 6-hour 
experiment (as opposed to simply drying off residual solution with a paper tissue), the LSCM 
images were significantly different. Using the dual-labelled polystyrene NP, post-cleaning there 
was very little green fluorescence visible (Figure 4.8a) other than that probably attributable to 
skin autofluorescence. In contrast, red fluorescence from NR was clearly visible around the 
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corneocytes, presumably reflecting the affinity of the lipophilic “active” for the SC intercellular 
lipid domains Figure 4.8b). Self-evidently, the overlay (Figure 4.8c) of Figures 4.8a and 4.8b 
reveals only the NR released from the NP prior to their removal by the surface cleaning 
procedure.  
 
Further examination of the treated skin by optically sectioning the tissue in 1μm steps is 
shown in Figure 4.8d. The uptake of NR into the deeper SC is apparent. The appearance of green 
background autofluorescence can also be seen and demonstrates no greater intensity than that 
seen in control (untreated) samples, confirming that this signal is not due to the presence of the 
fluorescently-labelled polymer (data not shown).  
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Figure 4.8: LSCM images (×63) from skin treated with fluorescently-labelled polystyrene NP 
(31 nm diameter) containing the model active. At the end of a 6-hour application, the skin surface 
was cleaned thoroughly with buffer and then dried. Panel a shows an almost complete absence of 
fluorescent NP at the surface suggesting that residual formulations had been effectively removed 
by washing. In contrast, panel b shows that NR had been released from the NP and had entered 
the lipid-rich intercellular space between the corneocytes. The overlay (panel c) and the 1 μm 
optical sections down to 10 μm confirm the uptake of “active” into the deeper SC; the weak 
autofluorescence of the skin itself becomes progressively apparent in the later sections. 
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The results from the poly-(methyl methacrylate) NP, when the skin surface is properly cleaned 
at the end of the application period, are similar. Figure 4.9a shows that no residual fluorescence 
from the NP is visible on the skin. On the other hand, NR has been released from the NP and has 
remained on/within the SC post-cleaning (Figure 4.9b and overlay Figure 4.9c). Only on hair 
follicles were the NP incompletely removed by skin washing (Figure 4.9d), and co-localization 
with the “active” was apparent (Figures 4.9e and 4.9f).  
 
 
 
Figure 4.9: LSCM images from skin treated with fluorescently-labelled polymethylmethacrylate 
NP (69 nm diameter) containing NR. After a 6-hour application, the skin was thoroughly cleaned 
with buffer and dried. Panel a shows no residual presence of NP post-washing, while panel b (and 
overlay panel c) indicates that NR was released from the NP on/into the SC. Only on hair 
follicles were NP retained after cleaning (panel d) and co-localization of NR on these appendages 
was observed (panel e and overlay panel f). 
4.5 Discussion 
 
The confocal images presented in Figures 4.6 - 4.9 allow the following, principal conclusions 
to be drawn: (a) NP made of polystyrene or polymethylmethacrylate do not appear able to pass 
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beyond the most superficial layers of the SC following a topical application lasting 6 hours; (b) 
the NP show affinity for sequestration in skin furrows and on and around follicles; thorough 
cleaning can remove the former but not necessarily the latter; (c) the associated hydrophobic 
active (NR) is released from the NP and is able to diffuse into the deeper layers of the SC, from 
which it is not removed by surface cleaning.  
 
The lack of penetration of NP across intact SC is perhaps not too surprising. It is difficult to 
envisage how a NP might traverse the SC transcellularly (which would involve uptake into 
corneocytes and translocalization through these cells). Equally, transport in the intercellular 
channels (100 nm width) of a ~50 nm diameter particle also seems unlikely given that the 
intercorneocyte space is filled with multiple lipid bilayers. The rigidity of the NP used in this 
study further undermines the possibility of their permeation across the barrier, as has been 
suggested in earlier work comparing the uptake of a lipophilic sunscreen from a nanoemulsion 
and from rigid NP made of cellulose acetate phthalate [5]. Parenthetically, from a practical 
standpoint, the fact that NP are retarded at the skin surface may be a distinct advantage for a 
sunscreen formulation, especially if they are able to create an occlusive film as well, from which 
the active may be slowly released over a prolonged period [14].  
 
The issue of particle rigidity has also been addressed by comparing standard lipid-based 
vesicles with specially-designed elastic species [15, 16]. While the penetration of such elastic 
vesicles across the entire SC has not been equivocally demonstrated, evidence for enhanced 
“active” transport, and even for the presence of intact vesicles in deeper parts of the SC, has been 
reported [16].  
 
Certainly, as has been observed here, it is clear that an “active” associated with topically 
applied NP can be released from the carrier and diffuse into the SC [4, 17, 18]. As reported 
elsewhere [3, 6, 19, 20], the delivery of the “active” will depend upon its physicochemical 
properties, its interaction with the nano-carrier, the manner of its association with the particle 
(surface adhesion, encapsulation, or a mixture of the two), as well as the dimensions and 
properties (hydrophobicity, hydrophilicity, charge, biodegradability) of the NP themselves.  
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Further work may be anticipated to explore in greater depth the potential of NP formulations 
to target “actives” to the hair follicles, for example, or to create a homogeneous and substantive 
surface film from which prolonged and controlled release may be achieved. Equally, while the 
penetration of NP across intact SC seems unlikely to pose a toxicological concern, the risk 
associated with contact to a damaged or diseased skin barrier merits considerable additional 
research.  
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Abstract 
Purpose: To investigate ex vivo, the skin disposition of topically applied nanoparticles, 
composed of different proportions of polystyrene (PS) and poly-2-hydroxyethyl methacrylate 
(HEMA), and of an associated, model “active” (Nile Red). Methods: PS nanoparticles were 
prepared with 0, 5, 10 and 20% (w/w) HEMA, and were fluorescently labelled via the covalent 
incorporation of a small quantity of fluorescein methacrylate during the polymerization 
procedure. The fluorophore, Nile Red, acted as a model “active” and was associated with the 
nanoparticles during their preparation. The particles were characterised by dynamic light 
scattering, transmission electron microscopy and NMR. Nile Red loading was determined by 
ultracentrifugation. Skin uptake was assessed using porcine tissue in Franz diffusion cells 
following a 6-hour application of the nanoparticle formulation, and subsequent quantification by 
stratum corneum (SC) tape-stripping and confocal microscopy. Results: Nanoparticle diameters 
were less than 100 nm. Progressive introduction of HEMA into the particles decreased their 
hydrophobicity and reduced the extent to which Nile Red was associated with the nanocarriers 
(thereby lowering the effective applied dose). As a consequence, uptake of Nile Red into the skin, 
as assessed both by the amounts extracted from the SC tape-strips and by confocal microscopy, 
was less as the percentage HEMA increased. The confocal results also confirmed that the 
nanoparticles themselves were unable to move beyond the superficial SC layer, but did show 
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some affinity for hair follicle openings. Conclusions: The loading of a lipophilic “active” into 
nanoparticles, and its subsequent release when these formulations are applied topically, are 
sensitive to the composition and the relative hydrophobicity of the carrier.   
 
Keywords: Nanoparticles, skin, stratum corneum, polystyrene, 2-hydroxyethyl methacrylate 
(HEMA), Nile Red, laser scanning confocal microscopy (LSCM), tape-stripping.  
 
5.1 Introduction 
 
The stratum corneum is the thin (~15 µm) outermost layer of the skin. It has been described as a 
“brick and mortar” structure [1] in which corneocytes are embedded in an intercellular lipid matrix. 
The corneocytes are arranged in parallel, overlapping, multicellular stacks perpendicular to the skin 
surface. The excellent permeability barrier of the skin protects the body against the loss of 
endogenous substances and from environmental insult [2].  
 
Nanoparticles (NPs), incorporating drug or active ingredients have been employed in 
pharmaceutical and cosmetic formulations to increase transport into/across the skin, to improve the 
homogeneity of the vehicle’s distribution on the skin, and to modulate flexibly the release of the 
active to the surface [3-9]. This has proved useful, for example, for those vehicles which are able to 
form thin, occlusive films which retain photoprotective actives. Increasingly, the physicochemical 
properties of the nanoparticles (size, charge, etc.) that determine their behaviour once applied to the 
skin, and the kinetics with which an “active” is released, are being understood, and have formed the 
basis of earlier research upon which the present study builds.  
 
Here, four polystyrene (PS)-2-hydroxyethyl methacrylate (HEMA) NP formulations were 
prepared and tested on porcine skin. The influence of polymer hydrophobicity on the skin uptake of 
Nile Red (NR), a model “active” compound was investigated. As reported previously [10], a small 
amount of fluorescein methacrylate (FMA) was introduced into the polymerisation process to 
covalently label the nanoparticles and permit their disposition on and within the skin to be monitored 
as well. The structures of PS, FMA and HEMA are in Figure 5.1.  
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Figure 5.1: The chemical structures of polystyrene (PS), fluorescein methacrylate (FMA) and 
2-hydroxyethyl methacrylate (HEMA). 
 
5.2 Materials  
 
5.2.1 Tissue  
 
 Full thickness porcine skin was obtained from a local slaughterhouse. The skin was cleaned 
carefully under cold running water. The subcutaneous fat was removed with a scalpel. The 
remaining tissue was dermatomed to a thickness of ~750 µm. Finally, the dermatomed skin was 
stored frozen at -20°C for up to a maximum of one month before use.  
 
5.2.2 Chemicals 
 
Fluorescein O-Methacrylate (FMA, 97% pure), Nile Red (NR, analytical grade) and 
polystyrene (MW = 44,000) were purchased from Sigma-Aldrich (St. Louis, MO, USA).  
 
Styrene (99% GC), 2-hydroxyethyl methacrylate (HEMA, 98%) and potassium persulfate 
(KPS) were purchased from Sigma-Aldrich (Gillingham, Dorset, England). Other chemicals used 
were sodium dodecylsulphate (SDS, 99+% GC, Sigma-Aldrich, Japan), ruthenium tetroxide 
(Taab Labs, Aldermaston, England), chloroform-d1 (ISOTEC TM, Miamisburg, OH, USA).  
5.3 Methods 
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5.3.1 NP preparation 
 
Styrene was first purified by passage through an alumina column to remove inhibitors.  
Nanoparticles were then prepared in an inert nitrogen atmosphere by free radical polymerisation 
(Figure 5.2). Fluorescein methacrylate (FMA, 0.13 g) and Nile Red (NR, 0.01 g) were dissolved 
in a 13 g of mixture of styrene and 2-hydroxylethyl methacrylate (HEMA) and deoxygenated 
under N2. Four distinct compositions of the monomers were used containing, respectively, 0, 5, 
10 and 20% w/w HEMA. Sodium dodecylsulphate (SDS, 1 g), an emulsifier, and potassium 
persulphate (KPS, 0.1 g), a free radical initiator, were dissolved in 200 ml of distilled water in a 
round-bottomed flask and degassed under N2. This solution was then heated to ~75°C before the 
oil phase was added with vigorous stirring. Polymerisation and NP formation was carried out for 
3 hours. The resulting particles contained FMA covalently and randomly incorporated into the 
PS-HEMA polymer. NR was absorbed on/in the NP. 
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Figure 5.2: Preparation of styrene-2-hydroxyethyl methacrylate (HEMA)-fluorescein 
methacrylate (FMA) copolymers by emulsion radical copolymerization with potassium persulfate 
(KPS) at 75°C.  
 
5.3.2 NP characterization  
 
The mean size and polydispersity of the NP were measured by dynamic light scattering (DLS 
BI90Plus spectrophotometer, Brookhaven Instruments Corporation, NY, USA). NP morphology 
was observed on a JEOL (JEM-2000) transmission electron microscope (TEM) at an accelerating 
voltage of 120kV. Each sample was prepared by casting a drop of NP dispersion onto a 300-mesh 
copper grid covered with carbon film. TEM images of the NP were obtained as positively stained 
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preparations by placing samples in ruthenium tetroxide vapour for 1 hr [11].  
 
To determine the degree of Nile red incorporation into the nanoparticles, the formulations 
were filtered (0.45 µm nylon filters, Whatman, Japan) and then subjected to ultracentrifugation at 
17000 g for 3 h at 20°C. The supernatant was kept for analysis of Nile Red. The sediment was 
washed with distilled water to remove surfactant and again centrifuged 17000 g for 3 h. The 
resulting pellet was freeze-dried, and then dissolved in dichloromethane. Finally, Nile Red in this 
organic solvent was measured by HPLC (Dionex, Sunnyvale, CA, USA) with fluorescence 
detection at 559 nm and 630 nm for excitation and emission wavelengths, respectively. A 
Hypersil BDS C18 (5 µm) 250×4.6 mm column, was used and the mobile phase was 
dichloromethane pumped at a flow rate of 1 ml/min at 25°C. Each injection was 200 µl. The Nile 
Red retention time was 5.6 minutes. Nile Red in the supernatant was also measured by HPLC 
using a mobile phase comprising acetonitrile-water (80:20). The column, injection volume, and 
temperature were as above. The retention time in this case was 12.1 minutes. 1H-NMR spectra 
were recorded in deuterated chloroform (CDCl3) on a Bruker Avance™ III spectrometer 
(Billerica, MA, USA) operating at 400 MHz. Prior to analysis in CDCl3, the NP were washed 
with water and acetone to remove SDS and unreacted compounds, and freeze-dried (Heto 
PowerDry PL3000, Thermo Electron Corporation, Waltham, MA, USA).  
 
5.3.3 In vitro skin permeation  
 
Visible hairs on the skin were first trimmed as close as possible to the surface. Skin 
permeation experiments were performed in vertical Franz diffusion cells thermostated at 37°C. 
The excised tissue was clamped between the donor and receptor compartments exposing a 
diffusion area of 3.8 cm2. The receptor phase was physiological buffer (pH = 7.4); the donor 
compartment held 1 ml of the NP formulation and was covered with Parafilm. After an 
application lasting 6 hrs, the cell was dismantled, and the skin was immediately either examined 
by confocal microscopy or tape-stripped to determine the NR concentration profile across the SC. 
5.3.4 Laser scanning confocal microscopy (LSCM)  
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The treated skin was first cleaned with physiological buffer and dried with tissue. The skin 
was then examined using a LSM 510 Invert Laser Scanning Microscope (Carl Zeiss, Jena, 
Germany). The system was equipped with both an argon laser (excitation line at 488 nm) and a 
HeNe laser (excitation line at 543 nm). A Plan-Neofluar 10×/0.3 objective, an EC Plan-Neofluar 
40×/1.30 oil DIC M27 objective and a Plan-Apochromat 63×/1.40 oil DIC M27 objective were 
used. Confocal images were obtained in the plane parallel to the sample surface (xy-mode), or in 
the plane perpendicular (optical sectioning z-stack mode). 
 
5.3.5 Tape-stripping  
 
A validated tape-stripping procedure was used to assess the depth of NR penetration into the 
SC and to recover NR from the treated skin [12]. About 20 2.7×2.7 cm2 tapes were prepared 
(Scotch® No.845 Book Tape, 3M Media, Broken, Germany). To delimit a fixed area for tape 
stripping, a 5×5 cm square mask was prepared with a central aperture of 2 cm diameter. A strip of 
adhesive tape was pressed firmly onto the skin surface, and then removed in a single movement. 
The direction of stripping was changed with each tape to ensure a more uniform removal of the 
SC with fewer tape-strips. Before and after each tape-strip, transepidermal water loss (TEWL) 
across the skin was measured (Aquaflux, Biox Systems Ltd., London, UK) to provide an idea of 
when most of the SC had been removed and to signal the end of the tape-stripping process. This 
was considered appropriate when TEWL reached 80 g-1m-2h. The tapes were weighed before and 
after stripping to determine the mass of SC removed. As the density of the tissue is ~1 g/cm3 [13], 
the volume of SC removed by each strip is known (assuming uniform coverage of SC on the 
tape-strip [14]). Then, given that the area stripped is fixed, the thickness of SC removed as 
tape-stripping proceeds can be found.  
5.4 Results and discussion 
 
For each polymerisation, the measured conversions were > 90%. The individual NP were 
spherical and smooth, as shown by TEM (Figure 5.3). The mean diameter of the NP was less than 
100 nm, an observation confirmed by dynamic light scattering (DSC) (Table 5.1).  
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Figure 5.3: Transmission electron microscopy of nanoparticles stained with ruthenium tetroxide. 
(a) PS; (b) PS-HEMA (95/5); (c) PS-HEMA (90/10); (d) PS-HEMA (80/20). Scale bar = 100 nm.  
 
NR encapsulation varies inversely with the percentage of HEMA co-polymerized into the 
nanoparticles (Table 5.1). That is, as the hydrophobicity of the particles was reduced (by 
increasing the amount of HEMA relative to PS), the affinity of the lipophilic dye, Nile Red, for 
the polymer decreased proportionally. A relatively constant amount of Nile Red was recovered in 
the supernatant for all nanoparticles, and it is inferred that the remaining fraction of the dye was 
associated with surfactant micelles.  
 
Table 5.1: Properties of nanoparticle formulations 
Nanoparticle 
formulation 
Average 
diameter (nm) 
Polydispersity 
index 
% Nile Red 
associated 
% Nile Red in 
supernatant 
Polystyrene (PS) 73.8 0.092 73.15 ± 1.14 6.43 ± 0.48 
PS - 5% HEMA 45.8 0.120 59.42 ± 2.07 6.21 ± 0.35 
PS - 10% HEMA 43.2 0.130 41.06 ± 1.85 6.20 ± 0.33 
PS - 20% HEMA 36.7 0.165 17.66 ± 1.20 6.20 ± 0.35 
 
Proton NMR spectra of HEMA, polystyrene, and the copolymer are shown in Figure 5.4. The 
copolymer shows signals from polystyrene and HEMA even after extensive 
dissolution/reprecipitation. However, because of the polymerization reaction, the copolymers do 
not have signals at 5.6 and 6.1 ppm, which are present in HEMA’s spectrum. While we did not 
investigate the polymer microstructure in detail, the spectra revealed no evidence of formation of 
blocks of the two monomers.  
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Figure 5.4: 1H NMR spectra of HEMA (top), polystyrene (middle) and their copolymer (bottom). 
 
5.4.1 LSCM results  
 
The dual-fluorescently labeled nanoparticles permitted the simultaneous visualization of the 
disposition/penetration of the carriers and of the model active (Nile Red) on and within the 
superficial skin. Moreover, the treated skin could be mechanically cross-sectioned as well, 
enabling the distribution of the fluorescent probes to be visualized as a function of depth. In this 
case, the confocality of the microscope used permitted artifacts from the sectioning to be avoided 
[15, 16].  
 
Figure 5.5 shows LSCM images of skin treated with PS nanoparticles. Localisation and 
release of Nile Red in skin “furrows” is apparent in the images from the skin surface. However, 
the green fluorescence from the polymer itself is very weak, suggesting that the cleaning 
procedure efficiently removed the particles post-treatment. The cross-sectional images confirm 
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these observations and show that Nile Red is released and penetrates into the deeper SC, in 
agreement with the results from previous studies [17, 18]. The overlay images of green and red 
fluorescence reveal only the presence of the latter. The behaviour of PS nanoparticles containing 
5% HEMA is shown in Figure 5.6. It is apparent that less Nile Red uptake into the SC has taken 
place. Once again, the persistence of the particles themselves post-treatment and surface cleaning 
is poor although there is evidence in Figure 5.6d that the carriers have been noticeably retained 
on a hair stub, and that the Nile Red has remained largely associated with the polymer here. 
Again, this observation is consistent with earlier reports in the literature [17]. Figure 5.7 
continues the trend seen in Figure 5.6 and illustrates the disposition of PS nanoparticles with 10% 
HEMA. Affinity of the particles for follicular structures is clearly observed, with the Nile Red 
co-localised with the polymer. On the skin surface, in contrast, the model active has separated 
from the carrier. Finally, when the HEMA content in the PS nanoparticles is raised to 20%, the 
images post-treatment and surface cleaning reveal only very faint red fluorescence, with no sign 
of retained polymer as shown in Figure 5.8. In this case, the Nile Red loading is very low, such 
that the driving force for permeation (even supposing an efficient release from the nanoparticle) 
is low. Overall, the confocal experiments reveal that (i) introducing hydrophilicity into the 
nanoparticles alters their behaviour on skin; (ii) the disposition of an associated lipophilic 
“active” (Nile Red) is influenced by nanoparticle properties; (iii) increasing the percentage of 
HEMA in PS nanoparticles significantly reduces the uptake of Nile Red into the SC; and (iv) 
there is no evidence that nanoparticles can penetrate beyond superficial SC. The latter conclusion 
agrees completely with recent findings from multiphoton microscopy experiments tracking the 
fate of poly-(lactide-co-glycolide) nanoparticles in the SC [19]. 
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Figure 5.5: PS nanoparticle-treated skin surface (top) and cross-sectional images (below). (a) (d) 
Green fluorescence from the FMA, indicating the location of the polymer. (b) (e) Red 
fluorescence from Nile Red. (c) (f) Overlaid images of green and red fluorescence. 
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Figure 5.6: PS-5%HEMA nanoparticle-treated skin surface (top) and cross section images 
(below). (a) (d) Green fluorescence from the FMA, indicating the location of the polymer. (b) (e) 
Red fluorescence from Nile Red. (c) (f) Overlaid images of green and red fluorescence. 
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Figure 5.7: PS-10%HEMA nanoparticle-treated skin surface (top) and cross section images 
(below). (a) (d) Green fluorescence from the FMA, indicating the location of the polymer. (b) (e) 
Red fluorescence from Nile Red. (c) (f) Overlaid images of green and red fluorescence. 
 
 
   
 
Figure 5.8: PS-20%HEMA nanoparticle-treated skin surface (top). (a) Green fluorescence from 
the FMA, indicating the location of the polymer. (b) Red fluorescence from NR. (c) Overlaid 
image of green and red fluorescence. Red fluorescence was not observed in cross section skin 
samples, due to inefficient Nile Red penetration in the SC. 
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5.4.2 In vitro skin permeation experiments 
 
In all experiments, irrespective of the nanoparticle composition used, no fluorescence (red or 
green) was ever detected in the receptor phase, confirming the LSCM observations that the 
disposition of the various formulation compounds was constrained to the SC.    
 
  The SC concentration profiles of Nile Red delivered from the four different nanoparticle 
carriers are in Figure 5.9. From the concomitant measurements of TEWL and of the mass of SC 
removed on each tape, it was possible (as previously published [14]) to express the 
concentrations as a function of relative position within the SC, thereby correcting for differences 
in absolute SC thickness from one porcine skin sample to another. This approach is reflected in 
the good reproducibility in the obtained results, and the clear separation, in terms of Nile Red 
uptake, between the nanoparticle formulations. 
 
 
 
Figure 5.9: Concentration profiles of Nile Red across the SC as a function of relative depth into 
the membrane (n = 5, mean ± SD). Please note that 0 indicates the SC surface and 1 reflects the 
SC-stratum granulosum interface).  
 
The integrated amounts of active taken up from each PS-HEMA polymer are displayed in 
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Figure 5.10 and reinforce the fact that Nile Red penetration into the SC was significantly reduced 
with each increment in the percentage HEMA incorporated into the polymer. The diminishing 
load of Nile Red in the nanoparticles as the percentage HEMA was increased (Table 5.1) almost 
certainly underlies the trend in Figure 5.10. Indeed, if the average amounts of the dye taken up 
into the SC are divided by the fraction of the active eventually associated with the particles, the 
ratios are remarkably consistent: 0.17, 0.16, 0.15 and 0.07 for PS, PS–5% HEMA, PS–10% 
HEMA and PS–20% HEMA, respectively. The apparent divergence for the nanoparticles 
containing the greatest level of HEMA is probably due, at least in part, to the fact that detection 
of Nile Red in many of the SC tape-strips following treatment with this formulation was close to 
or below the limits of quantitation/detection. 
 
 
 
Figure 5.10: Total quantities (in µg) of Nile Red in the SC after a 6-hour application of four NP 
formulations. 
 
It is appropriate to point out that these findings concur with earlier work from our laboratory 
[20] in which the SC uptake of Nile Red was observed to decrease as the nanoparticle polymer 
was changed from PS to poly-caprolactone to cellulose acetate butyrate; in other words, as the 
polymer became progressively more hydrophilic. As has been seen here, despite employing the 
same amount of Nile Red in the nanoparticle preparation procedure, the quantity eventually 
associated with the carrier depends upon polymer properties, and becomes less and less as the 
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hydrophilicity is increased. 
 
5.5 Conclusions 
 
The incorporation of a lipophilic active into a series of PS nanoparticles was sensitive to the 
percentage of the hydrophilic co-polymer (HEMA) present. As a result, the uptake of the active 
into the skin, following topical application of the nanoparticle formulations, was less efficient as 
the hydrophobicity of the carriers decreased. Results from confocal microscopy and SC 
tape-stripping experiments underpin these conclusions and provide valuable tools, therefore, for 
the development and optimisation of future nanoparticle formulations.   
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Abstract 
 
The objective of this preliminary investigation was to examine the disposition of charged 
nanoparticles on and within the skin following their topical application and to explore whether 
the formulations have potential utility for the local delivery of an associated “active” substance. 
Three nanoparticles (~100 nm in diameter) were investigated: cationic amino-functionalized 
polystyrene, an anionic carboxy-functionalized polystyrene and anionic poly-(L-lactide). To track 
the fate of the particles, each was associated with the fluorophore, 
N-(2,6-diisopropylphenyl)-perylene-3,4-dicarboximine (PMI). Formulations were applied to 
excised skin for 6-hours. After cleaning the skin surface post-treatment, the skin was either 
examined by laser scanning confocal microscopy or subjected to repeated tape-stripping and 
subsequent analysis of the stratum corneum (SC) removed for the presence of PMI. The cationic 
nanoparticles showed clear affinity for the negatively-charged skin surface (in contrast to the 
anionic carriers) and delivered a significantly greater amount of the model “active” (PMI) into 
the SC. 
 
Keywords: Charged nanoparticles, skin, stratum corneum, confocal microscopy, tape-stripping.  
 
6.1 Introduction 
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The use of nanoparticles as constituents of topical formulations of drug and cosmetics is 
receiving significant attention [1-9]. It is clear that the nature of the particle, such as its size and 
composition, will influence the manner in which it interacts with the skin and the rate and extent 
with which it releases an associated “active” species into the stratum corneum (SC), the 
outermost, and principal barrier layer of the membrane [10, 11].  
 
As part of a wider-ranging investigation into the disposition of nanoparticles on the skin, this 
preliminary study considers the impact of using charged polymers to prepare the carriers. Given 
that an important perceived benefits of nanoparticles in topical formulations is their ability to 
persist on, or in close proximity to, the skin surface, and given that (under normal physiological 
conditions), the skin carries a net negative charge [12, 13], it seems logical to anticipate that 
nanoparticles supporting different overall charges would likely interact with the barrier in clearly 
distinctive manners.  
 
Here, the fates of those nanoparticle formulations (one cationic, two anionic), containing a 
fluorescent dye as a model “active” compound, are evaluated by confocal microscopy and by SC 
tape stripping following their application to the porcine skin in vitro (an accepted surrogate for 
the human barrier) [14, 15].  
 
6.2 Materials  
 
6.2.1 Tissue  
 
Full thickness porcine skin was obtained from a local slaughterhouse. The skin was cleaned 
carefully under cold running water. The subcutaneous fat was removed with a scalpel. The 
remaining tissue was dermatomed to a thickness of ~ 750 µm. Finally, the dermatomed skin was 
stored frozen at -20°C for up to a maximum of one month before use.  
 
6.2.2 Chemicals 
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N-(2,6-diisopropylphenyl)-perylene-3,4-dicarboximine (PMI) (BASF, Germany), ruthenium 
tetroxide (Taab Laboratories, Aldermaston, England), phosphotungstic acid (Agar Scientific Ltd., 
Stansted, UK). 
 
6.2.3 Nanoparticle formulations 
 
The three nanoparticle formulations considered were prepared from the following polymers: 
(a) positively-charged, amino-functionalized polystyrene (PS-NH3+), (b) negatively-charged, 
caroboxy-functionalized polystyrene (PS-CO2-), and (c) negatively charged, biodegradable 
poly-(L-lactide) (PLL-). The miniemulsion preparation method and subsequent characterization 
of the particles are reported in detail elsewhere [16]. The fluorophore PMI (structure in Figure 
6.1) was associated with each of the nanoparticles and provided a means with which to track the 
performance of the carriers once applied to the skin. Table 6.1 summarizes the key characteristics 
of the nanoparticles examined. 
 
N
O
O
 
Figure 6.1: Chemical structure of N-(2,6-diisopropylphenyl)-perylene-3,4-dicarboximine (PMI).  
 
Table 6.1: Key characteristics of nanoparticle formulations examined. 
NP formulations Particle size (nm) Solid content (wt %)
Zeta-potential 
(mV) 
Incorporated PMI 
(mg/g polymer) 
PS-NH3+ 115 2.5 48 0.51 
PS-CO2- 87 5.7 -21 0.29 
PLL- 138 2.6 -34 0.57 
 
6.3 Methods 
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6.3.1 Nanoparticle morphology  
 
Nanoparticles were observed on a JEOL JEM-2000 TEM at an accelerating voltage of 120kV. 
Each sample was prepared by casting a drop of the nanoparticle dispersion onto a 300-mesh 
copper grid covered with carbon film. TEM images were obtained either as positively stained 
preparations by placing samples in ruthenium tetroxide vapour for 1 hr or as negatively stained 
preparations by placing samples in phosphotungstic acid vapour for 1 hr.  
 
6.3.2 In vitro skin permeation experiments 
 
First, any visible hairs were trimmed as close as possible to the skin surface. Experiments 
were performed in vertical Franz diffusion cells thermostated at 37°C. The excised skin was 
clamped between the donor and receptor compartments exposing a diffusion area of 3.8 cm2. The 
receptor medium was physiological buffer (pH = 7.4); the donor solution was 1 ml of a 
nanoparticle dispersion formulation. After a 6-hour application under occlusive conditions, the 
cell was dismantled, and the skin surface was cleaned with buffer. The skin surface was either 
examined by confocal microscopy or subjected to repeated adhesive tape-stripping to determine 
the distribution of PMI across the SC [17]. 
 
6.3.3 Laser scanning confocal microscopy (LSCM)  
 
Confocal microscopy was performed with a LSM 510 Invert Laser Scanning Microscope (Carl 
Zeiss, Jena, Germany). The system was equipped with an argon laser at 488 nm. A Plan-Neofluar 
10×/0.3 objective was used. Confocal images were obtained in the plane parallel to the sample 
surface (xy-mode), or in the plane perpendicular (optical sectioning z-stack mode). 
 
6.3.4 Tape-stripping  
 
A validated SC tape-stripping procedure was used to recover PMI form the treated skin and to 
assess its spatial distribution in the barrier [18].  
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6.3.5 High performance liquid chromatography (HPLC)  
 
PMI on the tape strips was extracted into acetonitrile via their immersion in the solvent at least 12 
hrs.  These extracts were then filtered (Whatman PTFE filter, 0.45µm) into HPLC vials and assayed 
chromatographically (Dionex, Sunnyvale, CA, USA) with fluorescence detection at 479 nm and 539 
nm for excitation and emission wavelengths, respectively. A Hypersil BDS C18 (5 µm) 250×4.6 mm 
column, was used and the mobile phase was tetrohydrofuran pumped at a flow rate of 1 ml/min at 
25°C. Each injection was 200 µl. The PMI retention time was 8.5 minutes.  
 
6.4 Results and discussion 
 
The individual NP were round and smooth, (Figure 6.2) and their mean diameters were less 
than 150 nm.  
 
   
 
Figure 6.2: Transmission electron microscopy images of functionalized fluorescent nanoparticles. 
Left panel: Amino-functionalized polystyrene latex particles (PS-NH3+); Middle panel: 
Carboxyl-functionalized polystyrene latex particles (PS-CO2-); Right panel: Biodegradable poly 
(L-lactide) particles (PLL-). 
 
Immediately after dismantling the diffusion cells, and removing the remaining formulation 
(but before properly washing the surface), a macroscopic inspection of the skin revealed a 
striking difference between PS-NH3+ and PS-CO2- nanoparticles (Figure 6.3). A clear affinity for 
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the skin of the cationic formulation could be discerned, consistent of course with the net negative 
charge on the skin membrane. 
 
 
 
 
Figure 6.3: Illustrative photographs of skin treated with either cationic PS-NH3+ (left) or anionic 
PS-CO2- (right) prior to surface cleaning.  
 
Confocal images were observed either in the usual way by optically sectioning the tissue at 
progressively increasing depth, or following a mechanical cross section and examination of the 
sample beyond the cut plane to avoid any physical artifacts caused by the sectioning procedure 
[19].  
 
Figure 6.4 shows representative image from skin treated with PS-NH3+. Bright green 
fluorescence from PMI is seen at the surface, where the nanoparticles are likely to be 
concentrated, and across the SC (the much weaker signals from the deeper epidermis is due to the 
skin autofluorescence – control image not shown). These results contrast dramatically with those 
in Figure 6.5 and Figure 6.6 from skin treated with the anionic PS-CO2- and PLL-, respectively. 
For these nanoparticles, little evidences of either their retention on the skin surface or that they 
have significantly released PMI into the SC can be seen.  
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Figure 6.4: LSCM images (×10) of porcine skin following a 6-hour application of PS-NH3+ 
nanoparticles. Left panel: Skin surface image showing bright green fluorescence from PMI. Right 
panel: Image of a mechanical cross-section. PMI fluorescence is visualized only in the SC. 
 
 
  
 
Figure 6.5: LSCM images (×10) of porcine skin following a 6-hour application of PS-CO2- 
nanoparticles. Left panel: Skin surface image showing minimal fluorescence. Right panel: Image 
of a mechanical cross-section. PMI fluorescence is barely visible.  
 
 
 
 
CHAPTER 6 
- 143 - 
 
  
 
Figure 6.6: LSCM images (×10) of porcine skin following a 6-hour application of PLL- 
nanoparticles for 6-hour. Left panel: Skin surface image showing negligible fluorescence. Right 
panel: Image of a mechanical cross-section. The fluorescence is very weak in all skin layers. 
 
In the in vitro skin permeation experiments, independent of the nanoparticle formulation used, 
no PMI was ever detected in the receptor compartment; that is, PMI did not penetrate beyond the 
superficial SC, an observation consistent with the LSCM results.  
 
The SC tape-strips were extracted and the PMI in each layer was determined by HPLC. Before 
extraction, the pre-weighed tapes were weighed again to assess the mass of SC removed on each 
strip and hence the relative depth of PMI penetration into the membrane [20]. The SC 
concentration profiles of the fluorophore after a 6-hour application of the different nanoparticle 
formulations are shown in Figure 6.7, and the integrated, total uptakes of PMI into the SC are in 
Figure 6.8. There is a statistically significant difference observed with “delivery” of the active 
being clearly better from the cationic nanoparticles, as compared to those of opposite charge. The 
results concur with the LSCM observations and suggest that an electrostatic attraction between 
positively charged nanoparticles and the negatively-charged skin may offer an advantageous 
attribute to improve the transfer of an active from the formulations into the SC. 
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Figure 6.7: Concentration profiles of PMI across the SC (n = 5, mean ± SD). The relative depth 
of penetration is zero at the skin surface, and has a value of 1 at the SC-stratum granulosum 
interface. 
 
 
 
Figure 6.8: Uptake of PMI into the SC following a 6-hour application of three nanoparticle 
formulations. A one-way ANOVA shows that there is a significant difference (alpha < 0.05) 
between all the nanoparticle formulations considered. 
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6.5 Conclusions 
 
The isoelectric point of mammalian skin falls in the range of 4 to 5, conferring a net negative 
charge on the membrane under normal physiological conditions. Positively-charged nanoparticles, 
not unexpectedly, show a greater attraction to the skin than those of opposite charge, and offer a 
better opportunity for the delivery of an associated “active” compound into the stratum corneum.  
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Conclusions and perspectives 
 
7.1 Conclusions  
 
Nanoparticles (NP) are interesting and advantageous components to be incorporated into 
topical preparations, based on their unique physiochemical properties, such as transparency in 
solution, occlusive film formation, and small size. They can protect a sensitive “active” from 
degradation by the environment. Some specially designed NP can also modulate the release of 
the active into the skin.  
 
It is very important to understand the mechanism with which the active is delivered to the 
desired skin site after topical application of active-loaded NP formulation. In detail, the following 
basic questions have been addressed in this thesis: (i) What happens to the NP when they come 
into contact with the skin? Do they remain at the surface or penetrate at all into the different 
strata of the skin? Do they have a particular affinity for any specific structures (e.g., hair follicles)? 
(ii) What happens to the “active” encapsulated or associated with the NP? Does it remain with the 
particles, or is it released? If the latter, with what kinetics and at what location does this release 
take place? (iii) In what manner is the fate of the NP, and release of the “active” influenced by the 
size, hydrophobicity and charge of NP, and physicochemical properties of the “active”?  
 
To begin this project, methods for the preparation of polymeric nano/meso-particles were 
designed to meet the objectives of the work. The prepared NP were characterized by dynamic 
light scattering (DLS), transmission electron microscope (TEM) and NMR to guarantee the 
quality of formulations used in subsequent skin permeation experiments. Ultracentrifugation was 
utilized to assess the active associated with nanoparticles. Following skin permeation 
experiments on porcine skin, the tape-stripping technique was used to measure stratum corneum 
(SC) thickness and to determine the distribution profile and penetration depth of “active” in the 
skin. Laser scanning confocal microscopy (LSCM) observations confirmed the results obtained 
by tape-stripping. Importantly, LSCM distinguished the “fates” of the NP vehicle and of the 
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“active” on and within the skin.  
This chapter summarizes the conclusions obtained from different aspects of this research, 
including NP preparation and characterization, tape-stripping, LSCM, influence of particle size, 
hydrophobicity, and surface charge on NP topical application, and the “fates” of both the NP 
vehicle and the active.  
 
7.1.1 Nanoparticle preparation and characterization 
 
Basically, the NP used in this study were prepared by two techniques: free radical 
polymerization from monomers and miniemulsion solvent evaporation from preformed polymers.  
 
The advantage of free radical polymerization is that functional monomer, for example, 
fluorescent dye and charged surface groups, can react and covalently bind with the nanoparticle 
polymer, thus enabling the application of NP for different experimental purposes. In one part of 
this work, a fluorophore, fluorescein methacrylate (FMA), was reacted with styrene and methyl 
methacrylate to produce fluorescent nanoparticle vehicles. The preparation procedure is 
straightforward. Figure 7.1 shows the LSCM image of a thin layer of NP fluorescently labeled 
with FMA. A number of green fluorescent clusters of NP are seen spreading homogeneously in 
the observed sample area. As the magnification capability of LSCM is not high enough to see 
individual nanoparticles, only clusters of NP are recorded. A second fluorophore, Nile Red, was 
associated with NP as a lipophilic model “active”. With the two fluorescent probes, the “fates” of 
NP vehicle and of the active were successfully distinguished.  
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Figure 7.1: Laser scanning confocal microscopy (LSCM) image of NP fluorescently labeled with 
fluorescein methacrylate (FMA).  
 
The advantage of the classic miniemulsion solvent evaporation method is that the molecular 
weight of polymers forming the nanoparticles is precisely controlled, and consequently the 
particle size of nanoparticles falls in a narrow range. However, the disadvantage of this technique 
is the introduction of organic solvent in the fabrication process. The removal of the organic 
solvent is an essential step, but relatively difficult to perform, as the surfactant used in the 
formulation results in foams in the rotary evaporation system sometimes causing the formulation 
to reflux. To avoid this problem, the pressure of the system has to be reduced very slowly and 
regularly.   
 
Dynamic light scattering is a popular technique to determine the size distribution profile of 
small particles in solution. However, any particles present, including polymer residues, dust and 
even air bubbles, can bias the results. Therefore, transmission electron microscopy (TEM) was 
employed to confirm nanoparticle size. Prior to observation, TEM samples have to be 
appropriately stained. It was demonstrated here that polystyrene and poly-(methyl methacrylate) 
NP could be stained by ruthenium tetroxide and phosphotungstic acid, respectively. 
Poly-(L-lactide) NP could be stained by phosphotungstic acid, uranyl acetate and ruthenium 
tetroxide. TEM images of poly-(L-lactide) NP stained by these three compounds are shown in 
Figure 7.2. The results show that negative staining (staining the background) by phosphotungstic 
CHAPTER 7 
- 152 - 
acid is the best choice for poly-(L-lactide) NP. Thus, the importance of choosing an appropriate 
staining agent is emphasized for TEM examination of polymeric NP.  
  
   
 
Figure 7.2: Transmission electron microscopy (TEM) images of poly-(L-lactide) nanoparticles 
after staining in (a) phosphotungstic acid, (b) uranyl acetate, and (c) ruthenium tetroxide vapours. 
Scale bars in all three images represent 0.2 µm.  
 
7.1.2 Tape-stripping 
 
Tape-stripping was used to assess the depth of “active” penetration into the SC and to recover 
“active” from the treated skin. The thickness of SC removed as tape-stripping proceeds was also 
determined. The variability of SC thickness between different skins is clear, and therefore emphasizes 
the value of the determination of SC thickness when the disposition of “active” across the barrier is to 
be evaluated, as it means that all concentrations can be expressed on a common scale of SC 
penetration depth normalized by the total membrane depth.  
 
The concentration profiles of the active in porcine SC following delivery from different kinds 
of NP formulations show good reproducibility, indicating the validity of the tape stripping 
method.  
 
7.1.3 Laser scanning confocal microscopy (LSCM)  
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LSCM is a valuable tool to visualize fluorescently-labeled biological samples. It provides 
in-depth information of skin without perturbation or destruction of the sample. Additionally, in 
this work, skin samples were sometimes mechanically sectioned and then examined by LSCM at 
a plane beyond the cut surface (thereby avoiding artifacts associated with the sectioning 
procedure). The results obtained from cross-sectioned samples are in agreement with those 
obtained from the optical sections.  
 
7.1.4 Influence of particle size on Nile Red disposition in the SC  
 
Three NP formulations with average diameters of 90 nm, 260 nm, and 630 nm were used to 
elucidate the influence of particle size on Nile Red (NR) disposition in the SC. The results 
demonstrated NR was more efficiently transferred into the SC from the nano/meso-carriers as the 
particle size increased. The total amounts of NR delivered into the SC from 90 nm, 260 nm, and 
630 nm formulations were 0.023, 0.033, and 0.058 µg, respectively. As the precise localization of 
NR in the nano/mesoparticles is not known, an unambiguous explanation for the observations is 
not possible. However, if as suspected, NR is predominantly absorbed onto the particle surface, 
then the larger carriers obviously offer a smaller surface area and the “leaving tendency” of NR 
from the vehicle would be enhanced.  
 
7.1.5 Influence of hydrophobicity on Nile Red disposition in the SC 
 
Two groups of nanoparticle formulations, (i) polystyrene, poly-(ε-caprolactone), and cellulose 
acetate butyrate (CAB) nanoparticles, and (ii) polystyrene nanoparticles co-polymerized with 0, 5, 
10, and 20% 2-hydroxyethyl methacrylate (HEMA), were prepared to investigate the influence of 
hydrophobicity of NP on Nile Red disposition in the SC. The results from both experiments 
demonstrated that uptake of NR was greatest from the most hydrophobic polymer (PS) and least 
from the most hydrophilic polymers (CAB and PS-20%HEMA). These differences are dependent 
upon the different loadings of Nile Red in the different NP. The incorporation efficacy of 
lipophilic Nile Red decreases with decreasing hydrophobicity of the NP. Nile Red incorporation 
efficacy, uptake into the SC, and uptake normalized by different fractional loadings are 
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summarized in Table 1. The results show that, as expected, Nile Red release from the least 
hydrophobic nanoparticle into the lipophilic SC is favoured relative to that from the more 
hydrophobic polymers.   
 
Table 7.1: Nile Red incorporation efficacy, uptake into the SC, and uptake normalized by 
different fractional loadings. 
Formulations  
Nile Red incorporation 
efficacy (%) 
Nile Red uptake 
in the SC (µg) 
NR uptake in the SC 
normalized by its loading
PS-NR-NP 77 0.053 0.69 
CAPA-NR-NP 49 0.038 0.78 
CAB-NR-NP 24 0.029 1.20 
PS NP 73 0.126 0.17 
PS-5% HEMA NP 59 0.093 0.16 
PS-10% HEMA NP 41 0.058 0.15 
PS-20% HEMA NP 18 0.012 0.07 
 
7.1.6 Influence of surface charge on Nile Red disposition into the SC 
 
Cationic amino-functionalized polystyrene, an anionic carboxy-functionalized polystyrene and 
anionic poly-(L-lactide) NP were used to investigate the influence of surface charge of NP on 
N-(2,6-diisopropylphenyl)-perylene-3,4-dicarboximine (PMI) disposition into the SC. The results 
demonstrated a statistically significant difference with the “delivery” of PMI being greater from 
the cationic nanoparticles, as compared to those of opposite charge. As the isoelectric point of 
mammalian skin falls in the range of 4 to 5, conferring a net negative charge on the membrane 
under normal physiological conditions, positively-charged nanoparticles, not unexpectedly, show 
a greater attraction to the skin than negatively-charged nanoparticles, and offer a better 
opportunity for the delivery of an associated “active” compound into the stratum corneum.  
 
7.1.7 The “fates” of the nanoparticle vehicle and associated “active” 
 
The polymeric NP studied in all of our experiments did not penetrate beyond the superficial 
SC but showed some affinity for hair follicles. Dual fluorescently labeled polystyrene and 
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poly-(methyl methacrylate) NP enabled the distributions of the vehicle and associated “active” in 
the SC to be tracked independently. LSCM images showed that the NP vehicle and “active” were 
principally co-localized in the skin furrows and around the hair follicles. Surface cleaning with 
buffer mostly removed the NP vehicle but the “active’’ was able to diffuse into the SC. At the 
skin surface, Nile Red remained in part associated with NP, but release of the “active” clearly 
occurred to some extent followed by its penetration into deeper layers of the SC.  
 
7.2 Perspectives  
 
7.2.1 Assess toxicity of nanoparticles by topical application 
 
The skin penetration studies performed have enhanced the understanding of how nanoparticles 
interact with skin and have improved the design of studies to measure these interactions. A 
number of variables, which influence the skin disposition of NP and an associated “active” have 
been clarified. Suggestions for future work include:  
 
(a) The experiments described here and most previous studies have employed particles of 
~100 nm in diameter [1-3]. There remains a need to further evaluate smaller particles, such as 
quantum dots (< 20 nm). 
 
(b) Investigation of a range of formulation bases that could influence skin uptake of NP by 
altering skin structure or increasing the solubility of the NP in the skin [4]. This is important 
because ingredients that act as “penetration enhancers” are commonly incorporated in cosmetic 
preparations.  
 
(c) Investigation of NP penetration across compromised or diseased skin (e.g., in acne or 
eczema, post-shaving, or severe sunburn).  
 
7.2.2 Improve product homogeneity and persistence after topical application 
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The evaluation objectives would include:  
 (a) Characterization of surface properties for skin-care applications, specifically to improve 
film product homogeneity after application. (i.e., control of spreading) 
 (b) Improve product persistence (effect durability) after application (Figure 7.3 and 7.4), 
especially to enhance waterproof properties for suncare products, to optimize anti-penetration 
properties for preservatives and perfumes, and to explore methods for the co-formulation of 
particles as additives.  
 
 
 
Figure 7.3: Example of a good oil-in-water emulsion film structure post-application.  
 
 
 
Figure 7.4: Example of a poor oil-in-water emulsion film structure post-application.  
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7.2.3 Enhance topical bioavailability 
Techniques for active encapsulation need to be improved to enhance active skin bioavailability. 
The entrapment of actives during particle formation is a significant challenge involving a 
compromise between particle formation and active stability. The technological difficulties are 
such that efforts should be initially focussed upon the entrapment of actives after particle 
formation, especially concentrating upon: adsorption (hydrophobic)/complexation (ionic), and 
swelling with a common solvent. Evaluation of entrapment could use fluorescence probes (Nile 
Red, cationic dyes…) and confocal microscopy to assess encapsulation yields and release profiles 
(effects of solvent, pH, ionic strength).   
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